US20080070229A1 - Method for preserving organs for transplantation - Google Patents
Method for preserving organs for transplantation Download PDFInfo
- Publication number
- US20080070229A1 US20080070229A1 US11/944,377 US94437707A US2008070229A1 US 20080070229 A1 US20080070229 A1 US 20080070229A1 US 94437707 A US94437707 A US 94437707A US 2008070229 A1 US2008070229 A1 US 2008070229A1
- Authority
- US
- United States
- Prior art keywords
- organ
- tissue
- electromagnetic energy
- harvested
- power density
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0294—Electromagnetic, i.e. using electromagnetic radiation or electromagnetic fields
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
- F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
- F25D3/00—Devices using other cold materials; Devices using cold-storage bodies
- F25D3/02—Devices using other cold materials; Devices using cold-storage bodies using ice, e.g. ice-boxes
- F25D3/06—Movable containers
- F25D3/08—Movable containers portable, i.e. adapted to be carried personally
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
- F25B—REFRIGERATION MACHINES, PLANTS OR SYSTEMS; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS
- F25B21/00—Machines, plants or systems, using electric or magnetic effects
- F25B21/02—Machines, plants or systems, using electric or magnetic effects using Peltier effect; using Nernst-Ettinghausen effect
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
- F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
- F25D2331/00—Details or arrangements of other cooling or freezing apparatus not provided for in other groups of this subclass
- F25D2331/80—Type of cooled receptacles
- F25D2331/801—Bags
- F25D2331/8014—Bags for medical use
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
- F25D—REFRIGERATORS; COLD ROOMS; ICE-BOXES; COOLING OR FREEZING APPARATUS NOT OTHERWISE PROVIDED FOR
- F25D2331/00—Details or arrangements of other cooling or freezing apparatus not provided for in other groups of this subclass
- F25D2331/80—Type of cooled receptacles
- F25D2331/804—Boxes
Definitions
- the present invention relates to apparatus and methods for preserving tissue, such as harvested organs for transplant.
- kidney transplants are now performed at an annual rate of over 9,000, and heart transplants are performed at the rate of over 1,500 per year.
- rejection of the transplanted tissue due to the recipient's normal immune response and transplant-related pathophysiology in the graft tissue continues to be a major hurdle to successful transplantation.
- graft tissue quality is a major factor underlying graft rejection. The method of storing a donor organ once removed from the donor greatly impacts.
- a donor organ is harvested, the organ is preserved by storage in a portable hypothermic container under sterile conditions.
- methods to preserve donor tissue integrity have focused primarily on maintenance of properly hypothermic and sterile conditions.
- tissue integrity compromised after harvesting and during storage remains a barrier to improved long-term survival of organ transplants.
- ischemia and reperfusion injury negatively impact donor tissue quality.
- ischemic damage to the vascular endothelium can result in accelerated graft atherosclerosis, which adversely affects ultimate survival of the graft.
- compromised donor tissue contributes to other chronic pathologies in the graft that result in substantial rates of graft loss.
- the problem of compromised organ tissue integrity is a major factor contributing to inadequate supplies of organs for transplant. About one in four patients awaiting cardiac transplantation dies while waiting for a suitable donated heart, and similar supply problems plague candidate recipients of other organs. The waits are due in part to insufficient rates of organ donation from potential donors, but also due in part to insufficient progress in developing successful techniques for preserving donated organs beyond very limited time periods after harvesting. Recent advances in immunosuppressive therapy that otherwise after harvesting. Recent advances in immunosuppressive therapy that otherwise have made organ transplantation more feasible have merely exacerbated the problems of organ supply. Thus, a major hurdle in exploiting improved organ transplantation techniques has been the inability to extend safe preservation of donated organs beyond the currently accepted time limit of about four hours. Preservation time limits of a few hours effectively limit the geographic area within which a donated organ can be transported and still be successfully transplanted. Such time limits also make it difficult or impossible to meaningfully evaluate the donated organ before transplant.
- Known organ preservation approaches typically include hypothermic arrest and storage in a liquid medium or perfusate, such as known cardioplegic preservation solutions for hypothermic preservation of donated hearts.
- hypothermic arrest and storage in a liquid medium or perfusate such as known cardioplegic preservation solutions for hypothermic preservation of donated hearts.
- cardioplegic preservation solutions for hypothermic preservation of donated hearts.
- Such approaches still do not prevent myocardial damage due to ischemia, reperfusion, fluid and electrolyte imbalances leading to edema, and metabolic exhaustion at the cellular level leading to a degradation of high-energy phosphates, all known to be factors contributing substantially to tissue damage.
- normothermic preservation eliminates the need to arrest organ function and the need for hypothermic storage, and reduces reperfusion injury and other time dependent tissue injury associated especially with metabolic rundown and depletion of high-energy phosphates.
- known methods for extending organ preservation involve attempts to simulate near-normal physiologic conditions, using various approaches.
- One approach involves harvesting almost all the donor's organs and using the system to perfuse the needed organ under normothermic conditions.
- this approach is limited because of the myriad practical difficulties involved in removing and preserving heart, lungs, liver, pancreas, and kidneys all together and all in functioning condition.
- Another related approach to achieving extended extracorporeal preservation of a donor organ involves providing continuous sanguineous perfusion, while maintaining the donor organ in the normal functioning state.
- known approaches include apparatus, methods and physiologic media that create an extracorporeal circuit for sanguineously perfusing the harvested organ at normothermic temperatures, thus prolonging preservation of the harvested organ for up to about twenty-four hours or longer.
- such approaches remain relatively cumbersome, are relatively costly, are not readily amenable to transport because they involve fairly complex perfusion systems, and have met with limited success.
- High-energy laser radiation is now well accepted as a surgical tool for cutting, cauterizing, and ablating biological tissue.
- High-energy lasers are now routinely used for vaporizing superficial skin lesions and, and to make deep cuts.
- a laser For a laser to be suitable for use as a surgical laser, it must provide light energy at a power sufficient to heat tissue to temperatures over 50 C. Power outputs for surgical lasers vary from 1-5 W for vaporizing superficial tissue, to about 100 W for deep cutting.
- low level laser therapy involves therapeutic administration of laser energy to a patient at vastly lower power outputs than those used in high energy laser applications, resulting in desirable biostimulatory effects while leaving tissue undamaged.
- low energy laser irradiation reduces infarct size and left ventricular dilation, and enhances angiogenesis in the myocardium.
- Low level laser therapy has been described for treating pain, including headache and muscle pain, and inflammation.
- the use of low level laser therapy to accelerate bone remodeling and healing of fractures has also been described. (See, e.g., J. Tuner and L. Hode, Low LEVEL LASER THERAPY, Sweden:Prima Books, 113-16, 1999, which is herein incorporated by reference).
- known low level laser therapy methods are circumscribed by setting only certain selected parameters within specified limits.
- known methods are characterized by application of laser energy at a set wavelength using a laser source having a set power output.
- known methods are generally typified by selecting a wavelength of the power source, setting the power output of the laser source at very low levels of 5 mW to 100 mW, setting low dosages of at most about 1-10 Joule/cm 2 , and setting time periods of application of the laser energy at twenty seconds to minutes.
- other parameters can be varied in the use of low level laser therapy.
- known low level laser therapy methods have not addressed the multiple other factors that may contribute to the efficacy of low level laser therapy.
- a need thus remains for simple, portable and cost-effective apparatus and methods that provide the ability to extend the organ preservation period beyond accepted limits, while avoiding time-dependent tissue damage due to ischemia and reperfusion, and depletion of high-energy phosphates.
- a need also remains for apparatus and methods that help to overcome organ transplant rejection, and enhance the survival time of transplanted organs, by improving the tissue quality of transplanted organs.
- the light therapy apparatus and methods for preserving tissue, including organs, for transplant are based in part on the new and surprising discovery that applying electromagnetic energy to the tissue during transport, generally following explantation, appears to prevent or retard tissue damage in a harvested organ, thus extending the time period of preservation and helping to overcome transplant rejection by improving tissue quality in preserved organs.
- the electromagnetic energy that is applied falls within a select wavelength range and at a select range of power density (i.e., power per unit area)
- an apparatus for transporting living tissue such as an organ
- a tissue preserving container having an interior cooling chamber adapted to receive a tissue
- at least one light source mounted on the container so as to illuminate the interior cooling chamber from a multiplicity of directions, where said light source emits optical radiation which produces a biostimulative effect on a tissue, thereby preventing or retarding damage to said tissue during transport.
- one preferred method relates to preserving organs for transplant and includes delivering to a harvested organ an effective amount of electromagnetic energy, the electromagnetic energy having a wavelength in the visible to near-infrared wavelength range, wherein delivering the effective amount of electromagnetic energy comprises selecting a predetermined power density of electromagnetic energy.
- the electromagnetic energy is applied to harvested organs placed in a preservation medium or perfusate, and may be applied in a hypothermic environment, for example in a hypothermic container or chamber, or in a normothermic environment.
- the power density is selected to be about 0.01 mW/cm 2 to about 100 mW/cm 2 .
- Such method may further include selecting a power and dosage of the electromagnetic energy sufficient to deliver the predetermined power density of electromagnetic energy to the organ.
- the electromagnetic energy is then applied to multiple treatment points across the organ surface.
- the methods are particularly suitable for preserving solid organs for transplant such as heart, lung, kidney, liver, or pancreas, but may also be used to preserve other tissues or organs.
- the methods are further directed toward preventing or retarding rejection of a transplanted organ in a subject in need thereof, the method including delivering to a harvested organ before transplant into the subject an effective amount of electromagnetic energy wherein delivering the effective amount of electromagnetic energy comprises selecting a power density of the electromagnetic energy, preferably about 0.01 mW/cm 2 and less than about 100 mW/cm 2 .
- the media storage container has a base and side walls extending from the base, and the side walls have a plurality of openings therethrough, each opening configured to mate with an electromagnetic energy source, such as a laser energy source, to form a fluid tight seal.
- the media storage container is configured to suspend the harvested organ in a fluid preservation medium.
- the media storage container is suspended in a secondary container having a base and side walls extending therefrom, the secondary container configured to suspend the media storage container in a thermoregulatory fluid.
- a plurality of electromagnetic energy sources extend from the side walls, each electromagnetic energy source mating with one of the plurality of openings on the media storage container side walls to form a fluid tight seal against the thermoregulatory fluid.
- a secondary cover mates with the secondary container.
- the electromagnetic energy sources are configured to emit electromagnetic energy having a wavelength in the visible to near-infrared wavelength range at a power density selected from the range of about 1 mW/cm 2 to about 100 mW/cm 2 .
- the apparatus is used to apply electromagnetic energy at a selected power density to a harvested organ suspended in a preservation medium in the media storage container.
- the FIGURE is a perspective view of one embodiment of an apparatus for transporting tissue, such as an organ.
- the methods to preserve organs for transplant described herein may be practiced and described using, for example, a low level laser therapy apparatus such as that shown and described in U.S. Pat. No. 6,214,035, U.S. Pat. No. 6,267,780, U.S. Pat. No. 6,273,905 and U.S. Pat. No. 6,290,714, which are all herein incorporated by reference together with the references contained therein.
- a low level laser therapy apparatus such as that shown and described in U.S. Pat. No. 6,214,035, U.S. Pat. No. 6,267,780, U.S. Pat. No. 6,273,905 and U.S. Pat. No. 6,290,714, which are all herein incorporated by reference together with the references contained therein.
- they are practiced using an apparatus such as that shown in the FIGURE.
- a low level laser apparatus including a handheld probe for delivering the electromagnetic energy to the organ.
- the probe includes a laser energy source emitting electromagnetic energy having a wavelength in the visible to near-infrared wavelength range, i.e., from about 630 nm to about 904 nm.
- the probe includes, for example, a single laser diode that provides about 100 mW to about 500 mW of total power output, or multiple laser diodes that together are capable of providing at least about 100 mW to about 500 mW of total power output. Other embodiments provide lower total power output, for example, about 1 mW or about 25 mW.
- the actual power output is preferably variable using a control unit electronically coupled to the probe, so that power of the light energy emitted can be adjusted in accordance with power density calculations as described below.
- the diodes used are, for example, continuously emitting CGaAlAs laser diodes having a wavelength of about 830 nm.
- a plurality of such laser probes provide the light energy sources.
- the electromagnetic energy source is another type of source, for example a light-emitting diode (LED), or other light energy source, having a wavelength in the visible to near-infrared wavelength range.
- the level of coherence of a light energy source is not critical. A light energy source need not provide light having the same level of coherence as the light provided by a laser energy source.
- the electromagnetic energy has a wavelength in the visible to near-infrared wavelength range, and within a select range of power density (i.e., light intensity or power per unit area, in mW/cm 2 ).
- power density i.e., light intensity or power per unit area, in mW/cm 2 .
- the electromagnetic energy delivered to an organ or tissue has a power density of about 0.01 mW/cm 2 to about 100 mW/cm 2 and, independent of the power of the electromagnetic energy source used and the dosage of the energy used, appears to improve the tissue quality of the stored organ, and appears to enhance the preservation period of organs for transplant.
- the electromagnetic energy is applied to an organ stored hypothermically, i.e., under hypothermic arrest, or at least at a temperature below the normal body temperature of the organ.
- the electromagnetic energy is applied to an organ stored under normothermic conditions, i.e., at near-normal physiologic temperature and function. Under normothermic conditions, it is preferred that the electromagnetic energy is applied to an organ for which a perfusion system and gas-exchange system are supplied, such as that described in U.S. Pat. No. 6,046,046, which is herein incorporated by reference.
- the treatment parameters include one or more of the following and the preferred storage and transport apparatus have light sources capable of supplying energy having one or more of the following properties.
- Preferred power densities of light at the level of the target cells of the tissue are between about 0.01 mW/cm 2 and about 100 mW/cm 2 , including about 0.05, 0.1, 0.5, 1, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, and 90 mW/cm 2 .
- power densities above 100 mW/cm 2 including about 250 mW/cm 2 and about 1000 mW/cm 2 .
- the power density emitted by the source(s) will be substantially identical to the power density at the outside surface of the tissue or organ.
- preferred light energy sources are capable of emitting light energy having a total power output of at least about 1 mW to about 500 mW, including about 5, 10, 15, 20, 30, 50, 75, 100, 150, 200, 250, 300, and 400 mW, but may also be as high as about 1000 mW or below 1 mW, such as 0.01 mW.
- the light energy used for treatment has a wavelength in the visible to near-infrared wavelength range, i.e., from about 630 to about 904 nm, preferably about 780 nm to about 840 nm, including about 790, 800, 810, 820, and 830 nm.
- the light may contain a large number of wavelengths within this range, or it may be substantially monochromatic (i.e. one wavelength or a very narrow band of wavelengths).
- the treatment proceeds continuously during substantially the entire period of time that the organ or tissue is being stored or transported, for example, during the time between explantation of the tissue or organ from a donor to implantation of the tissue or organ into a recipient, which may be anywhere from a few minutes to several hours.
- the light energy may be continuously provided, or it may be pulsed. If the light is pulsed, the pulses are preferably at least about 10 ns long, including about 100 ns, 1 ms, 10 ms, and 100 ms, and occur at a frequency of up to about 1 kHz, including about 1 Hz, 10 Hz, 50 Hz, 100 Hz, 250 Hz, 500 Hz, and 750 Hz.
- electromagnetic energy delivered within a specified range of power densities provides a biostimulative effect on mitochondria to avoid degradation of high-energy phosphates that is known to contribute to tissue damage.
- the electromagnetic energy may also help to avoid other degradation mechanisms and/or enhance protective mechanisms or reactions in the tissue.
- the observed biostimulative effect helps to maintain cellular integrity and prevents or retards tissue damage during compromise of the organ's normal physiologic environment, i.e., during disruption of normal perfusion and function such as may occur during hypothermic or normothermic storage before transplant.
- organ refers to a structure of bodily tissue in mammal such as a human being wherein the tissue structure as a whole is specialized to perform a particular body function.
- Organs that are transplanted within the meaning of the present methods include skin, cornea, heart, lung, kidney, liver and pancreas.
- Solid organs include the heart, lung, kidney, liver and pancreas.
- transplant refers to any organ or body tissue that has been transferred from its site of origin to a recipient site. Specifically in an allograft transplant procedure, the site of origin of the transplant is in a donor individual and the recipient site is in another, recipient individual.
- rejection refers to the process or processes by which the immune response of an organ transplant recipient mounts a reaction against the transplanted organ sufficient to impair or destroy normal function of the organ.
- the immune system response can involve specific (antibody and T cell-dependent) or non-specific (phagocytic, complement-dependent, etc.) mechanisms, or both.
- tissue damage refers to a characteristic of an amount of electromagnetic energy wherein the amount of electromagnetic energy achieves the goal of preventing, avoiding or retarding tissue damage in tissue, such as a harvested organ, whether the tissue damage results from ischemia, reperfusion, degradation of high-energy phosphates, inflammatory responses, edema, or any other tissue response to a stimulus such as the disruption of function and the manipulation that attends harvesting and storage of the organ.
- one preferred method is directed toward preserving a harvested organ for transplant include delivering to the harvested organ an effective amount of electromagnetic energy, the electromagnetic energy having a wavelength in the visible to near-infrared wavelength range, wherein delivering the effective amount of electromagnetic energy comprises delivering a predetermined power density of the electromagnetic energy to the organ.
- delivering the predetermined power density of electromagnetic energy to the harvested organ involves selecting the predetermined power density to be delivered, selecting a power and dosage of the electromagnetic energy sufficient to deliver the predetermined power density of electromagnetic energy to the organ, and applying the electromagnetic energy to at least one treatment point on a surface of the organ.
- the type and size of the organ being treated may be considered, and an appropriate dosage and power of the electromagnetic energy selected.
- the appropriate dosage and power of energy are any combination of power and dosage sufficient to deliver the predetermined power density of electromagnetic energy to the organ.
- the dosage and power should be sufficient for the electromagnetic energy to penetrate any body tissue such as connective tissue or fat that may be interposed between the surface of the organ and the electromagnetic energy source or any preservation medium or other material that may come between the tissue and the light source(s).
- the selected dosage and power of the electromagnetic energy should be sufficient to traverse any distance interposed between the electromagnetic energy source and the surface of the organ.
- the methods and apparatus are especially suitable for preserving for transplant any solid organ, such as a heart, a lung, a kidney, a liver, or a pancreas.
- any solid organ such as a heart, a lung, a kidney, a liver, or a pancreas.
- other tissues and other organs such as skin and cornea may also be beneficially treated using the methods and apparatus.
- the specific power density selected for treating any specific harvested organ will be dependent upon a variety of factors including especially the type (i.e., heart, liver, etc.) and size of the organ, the wavelength of the electromagnetic energy selected, whether the electromagnetic energy is being applied to an organ under hypothermic; arrest or under normothermic conditions, and the expected preservation time.
- the particular power density and other treatment parameters can be chosen to tailor the treatment to the individual organ transplant situation as is understood and determinable by one of skill in the art.
- a relatively greater surface power density of the electromagnetic energy is calculated taking into account any attenuation of the energy as it travels from the energy source to a treatment point on the surface of the organ, and through the organ tissue itself, For example, to deliver a predetermined power density of electromagnetic energy deeply within a relatively more massive organ such as a liver will require a greater surface power density than to deliver the same predetermined power density to a relatively less massive organ such as a pancreas.
- Factors known to affect penetration and to be taken into account in the calculation of the required surface power density include pigmentation and blood content, tissue type (myocardial, renal, etc.), and overall organ size and depth of internal tissue relative to surface treatment points.
- a desired power density of about 10 mW/cm 2 at a site within an organ at a depth of 3 cm below the organ surface may require a surface power density of 400 mW/cm 2 .
- the higher the level of pigmentation the higher the required surface power density to deliver a predetermined power density of electromagnetic energy to a subsurface site being treated
- the electromagnetic energy source for example a hand-held laser probe, is sterilized and placed in contact with a treatment point on a surface of the harvested organ.
- the electromagnetic energy source is positioned over a treatment point on the organ surface, but held some distance away from the treatment point.
- a surface power density calculation is made taking into account factors including the wavelength of the electromagnetic energy being used, the power density that has been selected from the power density range of about 1 mW/cm 2 to about 100 mW/cm 2 , the depth of tissue being treated, the extent and type of any intervening body tissue such as fat or connective tissue between the energy source and the organ surface, pigmentation, and the like that affect energy penetration and thus the power density that is actually received at the organ treatment point and any depth therebelow. Power of the energy source being used and the surface area of the treatment point are accordingly adjusted to obtain a surface power density sufficient to deliver the predetermined power density of electromagnetic energy to the organ at a given depth within the tissue. The electromagnetic energy source is then energized and the selected power density of electromagnetic energy delivered to the organ.
- the electromagnetic energy is applied to at least one treatment point on the organ, the treatment point having a diameter of about 1 cm.
- the electromagnetic energy is applied sequentially to a series of multiple treatment spots having centers that are separated by at least about 1 cm.
- the series of treatment spots can be mapped out over the surface of the organ to aid in an orderly progression of electromagnetic energy applications that systematically cover the surface area of the organ as it is being treated from any one approach.
- Some organs may be susceptible of treatment from more than one approach, i.e., treatment from the frontal and rear aspects of the organ, or from the frontal and side aspects.
- the required surface power density to deliver the predetermined power density of electromagnetic energy to the organ may change: depending on whether and how the depth of the organ tissue being treated relative to the organ surface changes, and any change in the nature and extent of any intervening tissue.
- the organ may be treated by applying the electromagnetic energy to two or more spots simultaneously, or to the entire organ at once.
- the precise power density selected for treating the organ is determined according to the judgment of a trained healthcare provider or light therapy technician and depends on a number of factors, including the specific wavelength of electromagnetic energy selected, and clinical factors such as type of organ being treated, the current survival time of the organ, the expected preservation time, whether the organ is being preserved under hypothermic arrest or under normothermic conditions, and the like. It should be understood that the power density of electromagnetic energy might be adjusted as preservation time elapses, or for use in combination with any other preservation agent or agents, especially agents added to a preservation medium or perfusate to achieve the desired effect of reducing tissue damage during preservation.
- the electromagnetic energy therapy can be applied on a regular basis such every quarter- or half-hour, or hourly, or any other suitable period of time.
- an apparatus for preserving a harvested organ for transplant is a “light box,” including generally a media storage container for receiving the harvested organ and suspending the organ in a fluid preservation medium or perfusate, and means for applying electromagnetic energy in accordance with the methods described above, i.e., at a selected power density, and wavelength, to the organ therein contained.
- the basic configuration of one preferred type of “light box” is, for example, described in U.S. Pat. No. 4,951,482, which is herein incorporated by reference.
- the apparatus is a portable container suitable for hypothermic transport of donor organs, and includes a media storage container having a base and side walls extending from the base.
- the side walls have a plurality of openings therethrough, each opening configured to mate with an electromagnetic energy source, such as a laser probe as described supra, or LED or other light source, to form a fluid tight seal.
- the openings are configured, for example, with threads and an O-ring type gasket, the threads configured to mate with threads on an end of a laser probe serving as a laser energy source.
- the media storage container is configured to allow for suspension of the harvested organ in a fluid preservation medium, and a primary cover mates with the media storage container to form a fluid-tight seal.
- the apparatus further includes a secondary container having a base and side walls extending therefrom, and is configured to suspend the media storage container in a thermoregulatory fluid.
- a plurality of electromagnetic energy sources extend from the side walls of the secondary container.
- each energy source mates with one of the plurality of openings on the media storage container side walls to form a fluid-tight seal against a thermoregulatory fluid contained in the secondary container.
- the fluid-tight seal of the primary cover with the media storage container seals inside of the media storage container against the thermoregulatory fluid.
- the energy source(s) are preferably configured to emit light energy having one or more of the characteristics described supra.
- the energy sources and organ are positioned relative to one another so that the energy sources direct the energy at the organ contained in the media storage container.
- a secondary cover mates with the secondary container to contain a thermoregulatory fluid.
- the media storage container is sized appropriately to receive and secure a large solid organ up to about the size of an adult human liver or lung.
- the secondary container is sized appropriately to receive the media storage container and a sufficient amount of thermoregulatory fluid to properly maintain the hypothermic arrest of the organ, while yet remaining sufficiently compact that a single individual adult is able to carry or otherwise transport the apparatus.
- the apparatus and methods can be varied for application to organs maintained in a normothermic environment, e.g., in an environment at near-normal physiologic temperature while maintaining near-normal organ function.
- a normothermic environment e.g., in an environment at near-normal physiologic temperature while maintaining near-normal organ function.
- the light energy will be applied to an organ for which a perfusion system and gas-exchange system are supplied, such as that described in U.S. Pat. No. 6,046,046, which is herein incorporated by reference.
- the apparatus includes a container to receive and hold the tissue or organ.
- the container comprises a bottom portion 10 and a cover 12 .
- the bottom portion 10 may be any suitable shape including, but not limited to, those having a base and at least one wall, such as the generally cylindrical shape illustrated in the FIGURE.
- the shape of the interior of the bottom portion may or may not correspond to its exterior shape.
- the bottom portion of an embodiment may have a generally cubic exterior yet have a hemispherical shaped interior.
- the exterior of the bottom portion 10 has at least one flat surface, preferably opposite the open end which mates with or engages the cover 12 , so as to provide a stable resting surface for the apparatus.
- the cover 12 is shaped so as to mate with the bottom portion.
- the cover 12 and bottom portion 10 form a fluid-tight seal when placed together to aid in containment of any storage or preservation medium or bodily fluids that may be associated with the organ or tissue.
- the cover 12 and bottom portion 10 need not be two separate, removable pieces as illustrated; they may be single piece construction or attached together such as by a hinge or other such mechanism.
- the cover 12 and bottom portion 10 may further comprise a locking or latching mechanism, engaging threads or other suitable means for securing the two pieces together.
- a handle may also be included to assist in transporting the apparatus.
- the cover 12 and/or the bottom portion 10 have at least one light source 14 mounted thereon to provide the electromagnetic energy to the tissue.
- the light sources may be separate or a single electromagnetic energy emitter may be used to provide light to two or more sources 14 simultaneously or in some sequence.
- the source(s) illuminate the interior from a plurality of directions.
- the source(s) 14 is attached to a controller (not illustrated) that is set or programmed to deliver light having characteritics as desired for treatment, including, but not limited to, wavelength, power, pulse duration, pulse frequency, and, in some embodiments, to vary the treatment parameters over time.
- the bottom portion 10 further comprises a shelf or elevated portion upon which the organ or tissue is placed to provide spatial separation between the organ or tissue and one or more sources 14 .
- the interior of at least the bottom portion 10 forms a cooling chamber to allow for storage and transport of the tissue received therein at a lowered temperature, including temperatures sufficient to cause hypothermic arrest.
- the cooling chamber is cooled by any suitable method or means.
- one or more walls 16 of the bottom portion have a cooling means disposed therein, including, but not limited to, electric (or battery) powered cooling equipment (e.g. heat pump, refrigeration, Peltier effect), thermoregulatory fluid, ice, “blue ice”, dry ice, and the like.
- the electromagnetic energy therapy methods and apparatus are used to enhance growth and function of organ-derived cell lines used in bioartificial organ support systems such as that described in U.S. Pat. No. 5,368,555 which is herein incorporated by reference.
- the electromagnetic energy is applied to a hepatic cell line that lines a hollow fiber cartridge.
- Biostimulation provided to the hepatocytes or other cell line enhances growth and function of the hepatocytes to perform key organ-specific functions in a subject for whom organ function is compromised. Improving the growth and function of such cell lines as used within such bioartificial organ support systems mitigates organ supply problems, especially for patients with acute and substantial loss of organ function.
Abstract
Description
- The present application is a divisional application of U.S. patent application Ser. No. 10/338,949, filed Jan. 8, 2003, incorporated in its entirety by reference herein, and which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application Nos. 60/347,171, filed Jan. 9, 2002, and 60/353,639, filed Jan. 31, 2002, the entireties of which are hereby incorporated by reference.
- The present invention relates to apparatus and methods for preserving tissue, such as harvested organs for transplant.
- Over the past thirty years, solid organ transplantation has become an increasingly viable treatment option for a variety of diseases and conditions. For example, in the United States alone, kidney transplants are now performed at an annual rate of over 9,000, and heart transplants are performed at the rate of over 1,500 per year. However, rejection of the transplanted tissue due to the recipient's normal immune response and transplant-related pathophysiology in the graft tissue continues to be a major hurdle to successful transplantation. In particular, graft tissue quality is a major factor underlying graft rejection. The method of storing a donor organ once removed from the donor greatly impacts.
- Typically, once a donor organ is harvested, the organ is preserved by storage in a portable hypothermic container under sterile conditions. Thus, methods to preserve donor tissue integrity have focused primarily on maintenance of properly hypothermic and sterile conditions. However, tissue integrity compromised after harvesting and during storage remains a barrier to improved long-term survival of organ transplants. Even under carefully monitored hypothermic and sterile conditions, ischemia and reperfusion injury negatively impact donor tissue quality. In particular, ischemic damage to the vascular endothelium can result in accelerated graft atherosclerosis, which adversely affects ultimate survival of the graft. In addition, compromised donor tissue contributes to other chronic pathologies in the graft that result in substantial rates of graft loss.
- The problem of compromised organ tissue integrity is a major factor contributing to inadequate supplies of organs for transplant. About one in four patients awaiting cardiac transplantation dies while waiting for a suitable donated heart, and similar supply problems plague candidate recipients of other organs. The waits are due in part to insufficient rates of organ donation from potential donors, but also due in part to insufficient progress in developing successful techniques for preserving donated organs beyond very limited time periods after harvesting. Recent advances in immunosuppressive therapy that otherwise after harvesting. Recent advances in immunosuppressive therapy that otherwise have made organ transplantation more feasible have merely exacerbated the problems of organ supply. Thus, a major hurdle in exploiting improved organ transplantation techniques has been the inability to extend safe preservation of donated organs beyond the currently accepted time limit of about four hours. Preservation time limits of a few hours effectively limit the geographic area within which a donated organ can be transported and still be successfully transplanted. Such time limits also make it difficult or impossible to meaningfully evaluate the donated organ before transplant.
- Known organ preservation approaches typically include hypothermic arrest and storage in a liquid medium or perfusate, such as known cardioplegic preservation solutions for hypothermic preservation of donated hearts. However, such approaches still do not prevent myocardial damage due to ischemia, reperfusion, fluid and electrolyte imbalances leading to edema, and metabolic exhaustion at the cellular level leading to a degradation of high-energy phosphates, all known to be factors contributing substantially to tissue damage.
- To avoid the problems associated with hypothermic arrest and storage, it is known in the art that normothermic preservation eliminates the need to arrest organ function and the need for hypothermic storage, and reduces reperfusion injury and other time dependent tissue injury associated especially with metabolic rundown and depletion of high-energy phosphates. Thus, known methods for extending organ preservation involve attempts to simulate near-normal physiologic conditions, using various approaches. One approach involves harvesting almost all the donor's organs and using the system to perfuse the needed organ under normothermic conditions. However, as an element of routine transplant practice, this approach is limited because of the myriad practical difficulties involved in removing and preserving heart, lungs, liver, pancreas, and kidneys all together and all in functioning condition. Another related approach to achieving extended extracorporeal preservation of a donor organ involves providing continuous sanguineous perfusion, while maintaining the donor organ in the normal functioning state. Thus, known approaches include apparatus, methods and physiologic media that create an extracorporeal circuit for sanguineously perfusing the harvested organ at normothermic temperatures, thus prolonging preservation of the harvested organ for up to about twenty-four hours or longer. However, such approaches remain relatively cumbersome, are relatively costly, are not readily amenable to transport because they involve fairly complex perfusion systems, and have met with limited success.
- In the field of surgery, high-energy laser radiation is now well accepted as a surgical tool for cutting, cauterizing, and ablating biological tissue. High-energy lasers are now routinely used for vaporizing superficial skin lesions and, and to make deep cuts. For a laser to be suitable for use as a surgical laser, it must provide light energy at a power sufficient to heat tissue to temperatures over 50 C. Power outputs for surgical lasers vary from 1-5 W for vaporizing superficial tissue, to about 100 W for deep cutting.
- In contrast, low level laser therapy involves therapeutic administration of laser energy to a patient at vastly lower power outputs than those used in high energy laser applications, resulting in desirable biostimulatory effects while leaving tissue undamaged. For example, in rat models of myocardial infarction and ischemia-reperfusion injury, low energy laser irradiation reduces infarct size and left ventricular dilation, and enhances angiogenesis in the myocardium. (Yaakobi et al., J. Appl. Physiol. 90, 2411-19 (2001)). Low level laser therapy has been described for treating pain, including headache and muscle pain, and inflammation. The use of low level laser therapy to accelerate bone remodeling and healing of fractures has also been described. (See, e.g., J. Tuner and L. Hode, Low LEVEL LASER THERAPY, Stockholm:Prima Books, 113-16, 1999, which is herein incorporated by reference).
- However, known low level laser therapy methods are circumscribed by setting only certain selected parameters within specified limits. For example, known methods are characterized by application of laser energy at a set wavelength using a laser source having a set power output. Specifically, known methods are generally typified by selecting a wavelength of the power source, setting the power output of the laser source at very low levels of 5 mW to 100 mW, setting low dosages of at most about 1-10 Joule/cm2, and setting time periods of application of the laser energy at twenty seconds to minutes. However, other parameters can be varied in the use of low level laser therapy. In particular, known low level laser therapy methods have not addressed the multiple other factors that may contribute to the efficacy of low level laser therapy.
- Against this background, a high level of interest remains in finding new and improved methods for preserving harvested organs for transplant thus to extend the time period for preservation. A need thus remains for simple, portable and cost-effective apparatus and methods that provide the ability to extend the organ preservation period beyond accepted limits, while avoiding time-dependent tissue damage due to ischemia and reperfusion, and depletion of high-energy phosphates. A need also remains for apparatus and methods that help to overcome organ transplant rejection, and enhance the survival time of transplanted organs, by improving the tissue quality of transplanted organs.
- The light therapy apparatus and methods for preserving tissue, including organs, for transplant are based in part on the new and surprising discovery that applying electromagnetic energy to the tissue during transport, generally following explantation, appears to prevent or retard tissue damage in a harvested organ, thus extending the time period of preservation and helping to overcome transplant rejection by improving tissue quality in preserved organs. Preferably the electromagnetic energy that is applied falls within a select wavelength range and at a select range of power density (i.e., power per unit area)
- In accordance with one embodiment, there is provided an apparatus for transporting living tissue, such as an organ, comprising a tissue preserving container having an interior cooling chamber adapted to receive a tissue, and at least one light source mounted on the container so as to illuminate the interior cooling chamber from a multiplicity of directions, where said light source emits optical radiation which produces a biostimulative effect on a tissue, thereby preventing or retarding damage to said tissue during transport.
- Thus, one preferred method relates to preserving organs for transplant and includes delivering to a harvested organ an effective amount of electromagnetic energy, the electromagnetic energy having a wavelength in the visible to near-infrared wavelength range, wherein delivering the effective amount of electromagnetic energy comprises selecting a predetermined power density of electromagnetic energy. The electromagnetic energy is applied to harvested organs placed in a preservation medium or perfusate, and may be applied in a hypothermic environment, for example in a hypothermic container or chamber, or in a normothermic environment. In a preferred embodiment, the power density is selected to be about 0.01 mW/cm2 to about 100 mW/cm2. To deliver the predetermined power density of electromagnetic energy to the organ, such method may further include selecting a power and dosage of the electromagnetic energy sufficient to deliver the predetermined power density of electromagnetic energy to the organ. The electromagnetic energy is then applied to multiple treatment points across the organ surface.
- The methods are particularly suitable for preserving solid organs for transplant such as heart, lung, kidney, liver, or pancreas, but may also be used to preserve other tissues or organs.
- The methods are further directed toward preventing or retarding rejection of a transplanted organ in a subject in need thereof, the method including delivering to a harvested organ before transplant into the subject an effective amount of electromagnetic energy wherein delivering the effective amount of electromagnetic energy comprises selecting a power density of the electromagnetic energy, preferably about 0.01 mW/cm2 and less than about 100 mW/cm2.
- In one embodiment, an apparatus for preserving tissue, such as a harvested organ for transplant includes a media storage container and a primary cover which mates with the media storage container to form a fluid-tight seal. The media storage container has a base and side walls extending from the base, and the side walls have a plurality of openings therethrough, each opening configured to mate with an electromagnetic energy source, such as a laser energy source, to form a fluid tight seal. The media storage container is configured to suspend the harvested organ in a fluid preservation medium. The media storage container is suspended in a secondary container having a base and side walls extending therefrom, the secondary container configured to suspend the media storage container in a thermoregulatory fluid. A plurality of electromagnetic energy sources extend from the side walls, each electromagnetic energy source mating with one of the plurality of openings on the media storage container side walls to form a fluid tight seal against the thermoregulatory fluid. A secondary cover mates with the secondary container. The electromagnetic energy sources are configured to emit electromagnetic energy having a wavelength in the visible to near-infrared wavelength range at a power density selected from the range of about 1 mW/cm2 to about 100 mW/cm2. The apparatus is used to apply electromagnetic energy at a selected power density to a harvested organ suspended in a preservation medium in the media storage container.
- The FIGURE is a perspective view of one embodiment of an apparatus for transporting tissue, such as an organ.
- The methods to preserve organs for transplant described herein may be practiced and described using, for example, a low level laser therapy apparatus such as that shown and described in U.S. Pat. No. 6,214,035, U.S. Pat. No. 6,267,780, U.S. Pat. No. 6,273,905 and U.S. Pat. No. 6,290,714, which are all herein incorporated by reference together with the references contained therein. In a preferred embodiment, they are practiced using an apparatus such as that shown in the FIGURE.
- In accordance with one embodiment of method to preserve organs for transplant is a low level laser apparatus including a handheld probe for delivering the electromagnetic energy to the organ. The probe includes a laser energy source emitting electromagnetic energy having a wavelength in the visible to near-infrared wavelength range, i.e., from about 630 nm to about 904 nm. The probe includes, for example, a single laser diode that provides about 100 mW to about 500 mW of total power output, or multiple laser diodes that together are capable of providing at least about 100 mW to about 500 mW of total power output. Other embodiments provide lower total power output, for example, about 1 mW or about 25 mW. The actual power output is preferably variable using a control unit electronically coupled to the probe, so that power of the light energy emitted can be adjusted in accordance with power density calculations as described below. The diodes used are, for example, continuously emitting CGaAlAs laser diodes having a wavelength of about 830 nm. In one embodiment of portable apparatus for tissue transport as described infra, a plurality of such laser probes provide the light energy sources. Alternatively, the electromagnetic energy source is another type of source, for example a light-emitting diode (LED), or other light energy source, having a wavelength in the visible to near-infrared wavelength range. The level of coherence of a light energy source is not critical. A light energy source need not provide light having the same level of coherence as the light provided by a laser energy source.
- In preferred methods, the electromagnetic energy has a wavelength in the visible to near-infrared wavelength range, and within a select range of power density (i.e., light intensity or power per unit area, in mW/cm2). The use of power densities within a particular range, as noted herein, appears to be a factor in producing beneficial effects for tissues, such as a harvested organ, thus enhancing preservation of the organ or tissue for transplant. In a preferred embodiment, the electromagnetic energy delivered to an organ or tissue has a power density of about 0.01 mW/cm2 to about 100 mW/cm2 and, independent of the power of the electromagnetic energy source used and the dosage of the energy used, appears to improve the tissue quality of the stored organ, and appears to enhance the preservation period of organs for transplant. In an exemplar embodiment, the electromagnetic energy is applied to an organ stored hypothermically, i.e., under hypothermic arrest, or at least at a temperature below the normal body temperature of the organ. Alternatively, the electromagnetic energy is applied to an organ stored under normothermic conditions, i.e., at near-normal physiologic temperature and function. Under normothermic conditions, it is preferred that the electromagnetic energy is applied to an organ for which a perfusion system and gas-exchange system are supplied, such as that described in U.S. Pat. No. 6,046,046, which is herein incorporated by reference.
- In preferred embodiments, the treatment parameters include one or more of the following and the preferred storage and transport apparatus have light sources capable of supplying energy having one or more of the following properties. Preferred power densities of light at the level of the target cells of the tissue are between about 0.01 mW/cm2 and about 100 mW/cm2, including about 0.05, 0.1, 0.5, 1, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, and 90 mW/cm2. In other embodiments, power densities above 100 mW/cm2, including about 250 mW/cm2 and about 1000 mW/cm2. In embodiments in which something surrounds the tissue or organ during treatment, such as when the organ is kept in contact with a medium such as a preservation medium or perfusate during storage and/or transport, or where it is placed in a bag or the like, one should take into account any possible attenuation of the energy as it travels through such surrounding material. In most embodiments, however, the power density emitted by the source(s) will be substantially identical to the power density at the outside surface of the tissue or organ. To achieve such power densities, preferred light energy sources, each alone or in combination, are capable of emitting light energy having a total power output of at least about 1 mW to about 500 mW, including about 5, 10, 15, 20, 30, 50, 75, 100, 150, 200, 250, 300, and 400 mW, but may also be as high as about 1000 mW or below 1 mW, such as 0.01 mW. Preferably the light energy used for treatment has a wavelength in the visible to near-infrared wavelength range, i.e., from about 630 to about 904 nm, preferably about 780 nm to about 840 nm, including about 790, 800, 810, 820, and 830 nm. The light may contain a large number of wavelengths within this range, or it may be substantially monochromatic (i.e. one wavelength or a very narrow band of wavelengths).
- In a preferred embodiment, the treatment proceeds continuously during substantially the entire period of time that the organ or tissue is being stored or transported, for example, during the time between explantation of the tissue or organ from a donor to implantation of the tissue or organ into a recipient, which may be anywhere from a few minutes to several hours. During the treatment, the light energy may be continuously provided, or it may be pulsed. If the light is pulsed, the pulses are preferably at least about 10 ns long, including about 100 ns, 1 ms, 10 ms, and 100 ms, and occur at a frequency of up to about 1 kHz, including about 1 Hz, 10 Hz, 50 Hz, 100 Hz, 250 Hz, 500 Hz, and 750 Hz.
- Without being bound by theory, it is believed that generally independently of the power and dosage of the electromagnetic energy used, electromagnetic energy delivered within a specified range of power densities provides a biostimulative effect on mitochondria to avoid degradation of high-energy phosphates that is known to contribute to tissue damage. The electromagnetic energy may also help to avoid other degradation mechanisms and/or enhance protective mechanisms or reactions in the tissue. In any case, the observed biostimulative effect helps to maintain cellular integrity and prevents or retards tissue damage during compromise of the organ's normal physiologic environment, i.e., during disruption of normal perfusion and function such as may occur during hypothermic or normothermic storage before transplant.
- The term “organ” as used herein refers to a structure of bodily tissue in mammal such as a human being wherein the tissue structure as a whole is specialized to perform a particular body function. Organs that are transplanted within the meaning of the present methods include skin, cornea, heart, lung, kidney, liver and pancreas. Solid organs include the heart, lung, kidney, liver and pancreas.
- The term “transplant” as used herein refers to any organ or body tissue that has been transferred from its site of origin to a recipient site. Specifically in an allograft transplant procedure, the site of origin of the transplant is in a donor individual and the recipient site is in another, recipient individual.
- The term “rejection” as used herein refers to the process or processes by which the immune response of an organ transplant recipient mounts a reaction against the transplanted organ sufficient to impair or destroy normal function of the organ. The immune system response can involve specific (antibody and T cell-dependent) or non-specific (phagocytic, complement-dependent, etc.) mechanisms, or both.
- The term “effective” as used herein refers to a characteristic of an amount of electromagnetic energy wherein the amount of electromagnetic energy achieves the goal of preventing, avoiding or retarding tissue damage in tissue, such as a harvested organ, whether the tissue damage results from ischemia, reperfusion, degradation of high-energy phosphates, inflammatory responses, edema, or any other tissue response to a stimulus such as the disruption of function and the manipulation that attends harvesting and storage of the organ.
- Thus, in a broad aspect, one preferred method is directed toward preserving a harvested organ for transplant include delivering to the harvested organ an effective amount of electromagnetic energy, the electromagnetic energy having a wavelength in the visible to near-infrared wavelength range, wherein delivering the effective amount of electromagnetic energy comprises delivering a predetermined power density of the electromagnetic energy to the organ. In a preferred embodiment, delivering the predetermined power density of electromagnetic energy to the harvested organ involves selecting the predetermined power density to be delivered, selecting a power and dosage of the electromagnetic energy sufficient to deliver the predetermined power density of electromagnetic energy to the organ, and applying the electromagnetic energy to at least one treatment point on a surface of the organ. To deliver the predetermined power density of electromagnetic energy to the organ, the type and size of the organ being treated may be considered, and an appropriate dosage and power of the electromagnetic energy selected. The appropriate dosage and power of energy are any combination of power and dosage sufficient to deliver the predetermined power density of electromagnetic energy to the organ. In addition, the dosage and power should be sufficient for the electromagnetic energy to penetrate any body tissue such as connective tissue or fat that may be interposed between the surface of the organ and the electromagnetic energy source or any preservation medium or other material that may come between the tissue and the light source(s). Further, the selected dosage and power of the electromagnetic energy should be sufficient to traverse any distance interposed between the electromagnetic energy source and the surface of the organ.
- The methods and apparatus are especially suitable for preserving for transplant any solid organ, such as a heart, a lung, a kidney, a liver, or a pancreas. However, other tissues and other organs such as skin and cornea may also be beneficially treated using the methods and apparatus.
- It is understood that the specific power density selected for treating any specific harvested organ will be dependent upon a variety of factors including especially the type (i.e., heart, liver, etc.) and size of the organ, the wavelength of the electromagnetic energy selected, whether the electromagnetic energy is being applied to an organ under hypothermic; arrest or under normothermic conditions, and the expected preservation time. Thus, the particular power density and other treatment parameters can be chosen to tailor the treatment to the individual organ transplant situation as is understood and determinable by one of skill in the art.
- To deliver the selected power density of electromagnetic energy to the interior of a harvested organ, a relatively greater surface power density of the electromagnetic energy is calculated taking into account any attenuation of the energy as it travels from the energy source to a treatment point on the surface of the organ, and through the organ tissue itself, For example, to deliver a predetermined power density of electromagnetic energy deeply within a relatively more massive organ such as a liver will require a greater surface power density than to deliver the same predetermined power density to a relatively less massive organ such as a pancreas. Factors known to affect penetration and to be taken into account in the calculation of the required surface power density include pigmentation and blood content, tissue type (myocardial, renal, etc.), and overall organ size and depth of internal tissue relative to surface treatment points. For example, to obtain a desired power density of about 10 mW/cm2 at a site within an organ at a depth of 3 cm below the organ surface may require a surface power density of 400 mW/cm2. In particular, the higher the level of pigmentation, the higher the required surface power density to deliver a predetermined power density of electromagnetic energy to a subsurface site being treated
- More specifically, to preserve an organ for transplant, the electromagnetic energy source, for example a hand-held laser probe, is sterilized and placed in contact with a treatment point on a surface of the harvested organ. Alternatively the electromagnetic energy source is positioned over a treatment point on the organ surface, but held some distance away from the treatment point. A surface power density calculation is made taking into account factors including the wavelength of the electromagnetic energy being used, the power density that has been selected from the power density range of about 1 mW/cm2 to about 100 mW/cm2, the depth of tissue being treated, the extent and type of any intervening body tissue such as fat or connective tissue between the energy source and the organ surface, pigmentation, and the like that affect energy penetration and thus the power density that is actually received at the organ treatment point and any depth therebelow. Power of the energy source being used and the surface area of the treatment point are accordingly adjusted to obtain a surface power density sufficient to deliver the predetermined power density of electromagnetic energy to the organ at a given depth within the tissue. The electromagnetic energy source is then energized and the selected power density of electromagnetic energy delivered to the organ.
- In an exemplary embodiment, the electromagnetic energy is applied to at least one treatment point on the organ, the treatment point having a diameter of about 1 cm. Thus, to most completely treat a harvested organ which typically will have a surface area substantially larger than a spot of a diameter of about 1 cm in accordance with this embodiment, the electromagnetic energy is applied sequentially to a series of multiple treatment spots having centers that are separated by at least about 1 cm. The series of treatment spots can be mapped out over the surface of the organ to aid in an orderly progression of electromagnetic energy applications that systematically cover the surface area of the organ as it is being treated from any one approach. Some organs may be susceptible of treatment from more than one approach, i.e., treatment from the frontal and rear aspects of the organ, or from the frontal and side aspects. As the approach is changed, the required surface power density to deliver the predetermined power density of electromagnetic energy to the organ may change: depending on whether and how the depth of the organ tissue being treated relative to the organ surface changes, and any change in the nature and extent of any intervening tissue. Alternatively, the organ may be treated by applying the electromagnetic energy to two or more spots simultaneously, or to the entire organ at once.
- Within a preferred power density range, the precise power density selected for treating the organ is determined according to the judgment of a trained healthcare provider or light therapy technician and depends on a number of factors, including the specific wavelength of electromagnetic energy selected, and clinical factors such as type of organ being treated, the current survival time of the organ, the expected preservation time, whether the organ is being preserved under hypothermic arrest or under normothermic conditions, and the like. It should be understood that the power density of electromagnetic energy might be adjusted as preservation time elapses, or for use in combination with any other preservation agent or agents, especially agents added to a preservation medium or perfusate to achieve the desired effect of reducing tissue damage during preservation. For example, as preservation time elapses, it will be expected that the number (i.e., number of treatment points) and/or frequency of electromagnetic energy treatments should increase, and/or the selected power density will increase to achieve the desired effect of reducing tissue damage during preservation. Generally, as long as the harvested organ remains viable, the electromagnetic energy therapy can be applied on a regular basis such every quarter- or half-hour, or hourly, or any other suitable period of time.
- In another aspect, there is provided an apparatus for preserving a harvested organ for transplant. In an exemplary embodiment, the apparatus is a “light box,” including generally a media storage container for receiving the harvested organ and suspending the organ in a fluid preservation medium or perfusate, and means for applying electromagnetic energy in accordance with the methods described above, i.e., at a selected power density, and wavelength, to the organ therein contained. The basic configuration of one preferred type of “light box” is, for example, described in U.S. Pat. No. 4,951,482, which is herein incorporated by reference.
- In an exemplary embodiment, the apparatus is a portable container suitable for hypothermic transport of donor organs, and includes a media storage container having a base and side walls extending from the base. The side walls have a plurality of openings therethrough, each opening configured to mate with an electromagnetic energy source, such as a laser probe as described supra, or LED or other light source, to form a fluid tight seal. The openings are configured, for example, with threads and an O-ring type gasket, the threads configured to mate with threads on an end of a laser probe serving as a laser energy source. The media storage container is configured to allow for suspension of the harvested organ in a fluid preservation medium, and a primary cover mates with the media storage container to form a fluid-tight seal. In this exemplary embodiment, the apparatus further includes a secondary container having a base and side walls extending therefrom, and is configured to suspend the media storage container in a thermoregulatory fluid. A plurality of electromagnetic energy sources, for example laser energy sources, extend from the side walls of the secondary container. In one embodiment, each energy source mates with one of the plurality of openings on the media storage container side walls to form a fluid-tight seal against a thermoregulatory fluid contained in the secondary container. Similarly, the fluid-tight seal of the primary cover with the media storage container seals inside of the media storage container against the thermoregulatory fluid. In accordance with the methods described herein, the energy source(s) are preferably configured to emit light energy having one or more of the characteristics described supra. The energy sources and organ are positioned relative to one another so that the energy sources direct the energy at the organ contained in the media storage container. In one embodiment, a secondary cover mates with the secondary container to contain a thermoregulatory fluid. The media storage container is sized appropriately to receive and secure a large solid organ up to about the size of an adult human liver or lung. The secondary container is sized appropriately to receive the media storage container and a sufficient amount of thermoregulatory fluid to properly maintain the hypothermic arrest of the organ, while yet remaining sufficiently compact that a single individual adult is able to carry or otherwise transport the apparatus. It will be appreciated that the apparatus and methods can be varied for application to organs maintained in a normothermic environment, e.g., in an environment at near-normal physiologic temperature while maintaining near-normal organ function. For example, under normothermic conditions the light energy will be applied to an organ for which a perfusion system and gas-exchange system are supplied, such as that described in U.S. Pat. No. 6,046,046, which is herein incorporated by reference.
- One preferred embodiment of tissue or organ transport apparatus is illustrated in the FIGURE. The apparatus includes a container to receive and hold the tissue or organ. The container comprises a
bottom portion 10 and acover 12. Thebottom portion 10 may be any suitable shape including, but not limited to, those having a base and at least one wall, such as the generally cylindrical shape illustrated in the FIGURE. The shape of the interior of the bottom portion may or may not correspond to its exterior shape. For example, the bottom portion of an embodiment may have a generally cubic exterior yet have a hemispherical shaped interior. In preferred embodiments, the exterior of thebottom portion 10 has at least one flat surface, preferably opposite the open end which mates with or engages thecover 12, so as to provide a stable resting surface for the apparatus. Thecover 12 is shaped so as to mate with the bottom portion. In a preferred embodiment, thecover 12 andbottom portion 10 form a fluid-tight seal when placed together to aid in containment of any storage or preservation medium or bodily fluids that may be associated with the organ or tissue. Thecover 12 andbottom portion 10 need not be two separate, removable pieces as illustrated; they may be single piece construction or attached together such as by a hinge or other such mechanism. Thecover 12 andbottom portion 10 may further comprise a locking or latching mechanism, engaging threads or other suitable means for securing the two pieces together. A handle may also be included to assist in transporting the apparatus. - The
cover 12 and/or thebottom portion 10 have at least onelight source 14 mounted thereon to provide the electromagnetic energy to the tissue. In embodiments having more than onesource 14, the light sources may be separate or a single electromagnetic energy emitter may be used to provide light to two ormore sources 14 simultaneously or in some sequence. In preferred embodiments, the source(s) illuminate the interior from a plurality of directions. In a preferred embodiment, the source(s) 14 is attached to a controller (not illustrated) that is set or programmed to deliver light having characteritics as desired for treatment, including, but not limited to, wavelength, power, pulse duration, pulse frequency, and, in some embodiments, to vary the treatment parameters over time. In one embodiment, thebottom portion 10 further comprises a shelf or elevated portion upon which the organ or tissue is placed to provide spatial separation between the organ or tissue and one ormore sources 14. - In preferred embodiments, the interior of at least the
bottom portion 10 forms a cooling chamber to allow for storage and transport of the tissue received therein at a lowered temperature, including temperatures sufficient to cause hypothermic arrest. The cooling chamber is cooled by any suitable method or means. In some preferred embodiments, one ormore walls 16 of the bottom portion have a cooling means disposed therein, including, but not limited to, electric (or battery) powered cooling equipment (e.g. heat pump, refrigeration, Peltier effect), thermoregulatory fluid, ice, “blue ice”, dry ice, and the like. - In another embodiment, the electromagnetic energy therapy methods and apparatus are used to enhance growth and function of organ-derived cell lines used in bioartificial organ support systems such as that described in U.S. Pat. No. 5,368,555 which is herein incorporated by reference. For example, the electromagnetic energy is applied to a hepatic cell line that lines a hollow fiber cartridge. Biostimulation provided to the hepatocytes or other cell line enhances growth and function of the hepatocytes to perform key organ-specific functions in a subject for whom organ function is compromised. Improving the growth and function of such cell lines as used within such bioartificial organ support systems mitigates organ supply problems, especially for patients with acute and substantial loss of organ function.
- The explanations and illustrations presented herein are intended to acquaint others skilled in the art with the invention, its principles, and its practical application. Those skilled in the art may adapt and apply the invention in its numerous forms, as may be best suited to the requirements of a particular use. Accordingly, the specific embodiments of the present invention as set forth are not intended as being exhaustive or limiting of the invention.
Claims (25)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/944,377 US20080070229A1 (en) | 2002-01-09 | 2007-11-21 | Method for preserving organs for transplantation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34717102P | 2002-01-09 | 2002-01-09 | |
US35363902P | 2002-01-31 | 2002-01-31 | |
US10/338,949 US7316922B2 (en) | 2002-01-09 | 2003-01-08 | Method for preserving organs for transplant |
US11/944,377 US20080070229A1 (en) | 2002-01-09 | 2007-11-21 | Method for preserving organs for transplantation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/338,949 Division US7316922B2 (en) | 2002-01-09 | 2003-01-08 | Method for preserving organs for transplant |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080070229A1 true US20080070229A1 (en) | 2008-03-20 |
Family
ID=26995155
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/338,949 Expired - Lifetime US7316922B2 (en) | 2002-01-09 | 2003-01-08 | Method for preserving organs for transplant |
US11/944,377 Abandoned US20080070229A1 (en) | 2002-01-09 | 2007-11-21 | Method for preserving organs for transplantation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/338,949 Expired - Lifetime US7316922B2 (en) | 2002-01-09 | 2003-01-08 | Method for preserving organs for transplant |
Country Status (3)
Country | Link |
---|---|
US (2) | US7316922B2 (en) |
AU (1) | AU2003207511A1 (en) |
WO (1) | WO2003060399A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080004565A1 (en) * | 2003-01-24 | 2008-01-03 | Jackson Streeter | Method of treating or preventing depression |
US20080125836A1 (en) * | 2006-08-24 | 2008-05-29 | Jackson Streeter | Low level light therapy for enhancement of neurologic function of a patient affected by parkinson's disease |
US20100003782A1 (en) * | 2008-07-02 | 2010-01-07 | Nishant Sinha | Methods Of Forming A Non-Volatile Resistive Oxide Memory Cell And Methods Of Forming A Non-Volatile Resistive Oxide Memory Array |
US20100016841A1 (en) * | 2006-01-30 | 2010-01-21 | Luis De Taboada | Light-emitting device and method for providing phototherapy to the brain |
US20110040356A1 (en) * | 2009-08-12 | 2011-02-17 | Fredric Schiffer | Methods for Treating Psychiatric Disorders Using Light Energy |
US20110102916A1 (en) * | 2008-09-18 | 2011-05-05 | Photo Thera, Inc. | Single-use lens assembly |
US8167921B2 (en) | 2003-01-24 | 2012-05-01 | Jackson Streeter | Low level light therapy for enhancement of neurologic function |
US8785116B2 (en) | 2012-08-10 | 2014-07-22 | Paragonix Technologies, Inc. | Methods for evaluating the suitability of an organ for transplant |
US8828710B2 (en) | 2011-03-15 | 2014-09-09 | Paragonix Technologies, Inc. | System for hypothermic transport of samples |
US8835158B2 (en) | 2011-03-15 | 2014-09-16 | Paragonix Technologics, Inc. | Apparatus for oxygenation and perfusion of tissue for organ preservation |
US20140311359A1 (en) * | 2012-03-16 | 2014-10-23 | Seung Won Lee | Storage apparatus for improving food preservation |
JP2015035999A (en) * | 2013-08-12 | 2015-02-23 | 株式会社コーナン・メディカル | Apparatus for observing cornea for transplantation, and auxiliary light source used for the same |
US9253976B2 (en) | 2011-03-15 | 2016-02-09 | Paragonix Technologies, Inc. | Methods and devices for preserving tissues |
US9426979B2 (en) | 2011-03-15 | 2016-08-30 | Paragonix Technologies, Inc. | Apparatus for oxygenation and perfusion of tissue for organ preservation |
US9560846B2 (en) | 2012-08-10 | 2017-02-07 | Paragonix Technologies, Inc. | System for hypothermic transport of biological samples |
US9610460B2 (en) | 2009-05-01 | 2017-04-04 | Wayne State University | Light therapy treatment |
US9867368B2 (en) | 2011-03-15 | 2018-01-16 | Paragonix Technologies, Inc. | System for hypothermic transport of samples |
USD819223S1 (en) | 2014-10-10 | 2018-05-29 | Paragonix Technologies, Inc. | Transporter for a tissue transport system |
US10071261B2 (en) | 2009-05-01 | 2018-09-11 | Wayne State University | Light therapy treatment |
US11166452B2 (en) | 2017-06-07 | 2021-11-09 | Paragonix Technologies, Inc. | Apparatus for tissue transport and preservation |
US11178866B2 (en) | 2011-03-15 | 2021-11-23 | Paragonix Technologies, Inc. | System for hypothermic transport of samples |
US11632951B2 (en) | 2020-01-31 | 2023-04-25 | Paragonix Technologies, Inc. | Apparatus for tissue transport and preservation |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL124722A0 (en) * | 1998-06-02 | 1999-01-26 | Oron Amir | Ischemia laser treatment |
US9993659B2 (en) * | 2001-11-01 | 2018-06-12 | Pthera, Llc | Low level light therapy for enhancement of neurologic function by altering axonal transport rate |
US10683494B2 (en) * | 2001-11-01 | 2020-06-16 | Pthera LLC | Enhanced stem cell therapy and stem cell production through the administration of low level light energy |
US20030144712A1 (en) * | 2001-12-20 | 2003-07-31 | Jackson Streeter, M.D. | Methods for overcoming organ transplant rejection |
US10695577B2 (en) * | 2001-12-21 | 2020-06-30 | Photothera, Inc. | Device and method for providing phototherapy to the heart |
US7316922B2 (en) * | 2002-01-09 | 2008-01-08 | Photothera Inc. | Method for preserving organs for transplant |
US20040153130A1 (en) * | 2002-05-29 | 2004-08-05 | Amir Oron | Methods for treating muscular dystrophy |
US20040170950A1 (en) * | 2002-09-12 | 2004-09-02 | Prien Samuel D. | Organ preservation apparatus and methods |
US20040132002A1 (en) * | 2002-09-17 | 2004-07-08 | Jackson Streeter | Methods for preserving blood |
US7344555B2 (en) * | 2003-04-07 | 2008-03-18 | The United States Of America As Represented By The Department Of Health And Human Services | Light promotes regeneration and functional recovery after spinal cord injury |
US20050153271A1 (en) * | 2004-01-13 | 2005-07-14 | Wenrich Marshall S. | Organ preservation apparatus and methods |
US10357662B2 (en) * | 2009-02-19 | 2019-07-23 | Pthera LLC | Apparatus and method for irradiating a surface with light |
US20070179570A1 (en) * | 2006-01-30 | 2007-08-02 | Luis De Taboada | Wearable device and method for providing phototherapy to the brain |
US20090254154A1 (en) * | 2008-03-18 | 2009-10-08 | Luis De Taboada | Method and apparatus for irradiating a surface with pulsed light |
US20080033412A1 (en) * | 2006-08-01 | 2008-02-07 | Harry Thomas Whelan | System and method for convergent light therapy having controllable dosimetry |
US20080145919A1 (en) * | 2006-12-18 | 2008-06-19 | Franklin Thomas D | Portable organ and tissue preservation apparatus, kit and methods |
US20080221211A1 (en) * | 2007-02-02 | 2008-09-11 | Jackson Streeter | Method of treatment of neurological injury or cancer by administration of dichloroacetate |
WO2008141296A1 (en) | 2007-05-11 | 2008-11-20 | Clarimedix | Visible light modulation of mitochondrial function in hypoxia and disease |
US20090263780A1 (en) * | 2008-04-17 | 2009-10-22 | Yanming Wang | Organ preservation fluid |
US9693825B2 (en) | 2008-12-14 | 2017-07-04 | C Laser, Inc. | Fiber embedded hollow needle for percutaneous delivery of laser energy |
US9265576B2 (en) | 2010-02-21 | 2016-02-23 | C Laser, Inc. | Laser generator for medical treatment |
US10206742B2 (en) | 2010-02-21 | 2019-02-19 | C Laser, Inc. | Fiber embedded hollow spikes for percutaneous delivery of laser energy |
US20130177898A1 (en) * | 2011-07-05 | 2013-07-11 | John Brassil | Method of Treating Organs |
US9040921B2 (en) | 2012-07-28 | 2015-05-26 | Harvard Apparatus Regenerative Technology, Inc. | Analytical methods |
US9781920B2 (en) * | 2014-04-09 | 2017-10-10 | Paul Jeffrey Campsen | Suspendable organ transplant system and method of use |
DE102015110860A1 (en) * | 2015-07-06 | 2017-01-12 | Wolfgang Bohn | Vitality preservation and quality improvement in the storage of vital biological materials |
US11458328B2 (en) | 2018-10-22 | 2022-10-04 | Joovv, Inc. | Photobiomodulation therapy device accessories |
US10478635B1 (en) | 2018-10-22 | 2019-11-19 | Joovv, Inc. | Photobiomodulation therapy systems and methods |
US11033752B2 (en) * | 2018-10-22 | 2021-06-15 | Joovv, Inc. | Photobiomodulation therapy systems and methods |
Citations (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3735755A (en) * | 1971-06-28 | 1973-05-29 | Interscience Research Inst | Noninvasive surgery method and apparatus |
US3810367A (en) * | 1970-07-16 | 1974-05-14 | W Peterson | Container for cooling, storage, and shipping of human organ for transplant |
US4315514A (en) * | 1980-05-08 | 1982-02-16 | William Drewes | Method and apparatus for selective cell destruction |
US4343301A (en) * | 1979-10-04 | 1982-08-10 | Robert Indech | Subcutaneous neural stimulation or local tissue destruction |
US4633872A (en) * | 1983-11-08 | 1987-01-06 | Hgm, Incorporated | Laser optical delivery apparatus |
US4669466A (en) * | 1985-01-16 | 1987-06-02 | Lri L.P. | Method and apparatus for analysis and correction of abnormal refractive errors of the eye |
US4798215A (en) * | 1984-03-15 | 1989-01-17 | Bsd Medical Corporation | Hyperthermia apparatus |
US4846196A (en) * | 1986-01-29 | 1989-07-11 | Wiksell Hans O T | Method and device for the hyperthermic treatment of tumors |
US4850351A (en) * | 1985-05-22 | 1989-07-25 | C. R. Bard, Inc. | Wire guided laser catheter |
US4930504A (en) * | 1987-11-13 | 1990-06-05 | Diamantopoulos Costas A | Device for biostimulation of tissue and method for treatment of tissue |
US4951482A (en) * | 1988-12-21 | 1990-08-28 | Gilbert Gary L | Hypothermic organ transport apparatus |
US4951653A (en) * | 1988-03-02 | 1990-08-28 | Laboratory Equipment, Corp. | Ultrasound brain lesioning system |
US5029581A (en) * | 1986-11-19 | 1991-07-09 | Fuji Electric Co., Ltd. | Laser therapeutic apparatus |
US5037374A (en) * | 1989-11-29 | 1991-08-06 | Carol Mark P | Stereotactic-guided radiation therapy system with variable-length compensating collimator |
US5150704A (en) * | 1986-06-23 | 1992-09-29 | Fuji Electric Co., Ltd. | Laser therapeutic apparatus |
US5282797A (en) * | 1989-05-30 | 1994-02-01 | Cyrus Chess | Method for treating cutaneous vascular lesions |
US5401270A (en) * | 1990-12-19 | 1995-03-28 | Carl-Zeiss-Stiftung | Applicator device for laser radiation |
US5441495A (en) * | 1989-08-17 | 1995-08-15 | Life Resonances, Inc. | Electromagnetic treatment therapy for stroke victim |
US5445146A (en) * | 1995-03-31 | 1995-08-29 | Bellinger; Gary J. | Biological tissue stimulation by low level optical energy |
US5445608A (en) * | 1993-08-16 | 1995-08-29 | James C. Chen | Method and apparatus for providing light-activated therapy |
US5501655A (en) * | 1992-03-31 | 1996-03-26 | Massachusetts Institute Of Technology | Apparatus and method for acoustic heat generation and hyperthermia |
US5511563A (en) * | 1991-06-21 | 1996-04-30 | Diamond; Donald A. | Apparatus and method for treating rheumatoid and psoriatic arthritis |
US5540737A (en) * | 1991-06-26 | 1996-07-30 | Massachusetts Institute Of Technology | Minimally invasive monopole phased array hyperthermia applicators and method for treating breast carcinomas |
US5601526A (en) * | 1991-12-20 | 1997-02-11 | Technomed Medical Systems | Ultrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects |
US5616140A (en) * | 1994-03-21 | 1997-04-01 | Prescott; Marvin | Method and apparatus for therapeutic laser treatment |
US5617258A (en) * | 1995-10-25 | 1997-04-01 | Plc Medical Systems, Inc. | Non-reusable lens cell for a surgical laser handpiece |
US5621091A (en) * | 1986-07-25 | 1997-04-15 | The Children's Medical Center Corporation | Probes for and nucleic acid encoding the muscular dystrophy protein, dystrophin |
US5622168A (en) * | 1992-11-18 | 1997-04-22 | John L. Essmyer | Conductive hydrogels and physiological electrodes and electrode assemblies therefrom |
US5627870A (en) * | 1993-06-07 | 1997-05-06 | Atea, Societe Atlantique De Techniques Avancees | Device for treating cerebral lesions by gamma radiation, and corresponding treatment apparatus |
US5640978A (en) * | 1991-11-06 | 1997-06-24 | Diolase Corporation | Method for pain relief using low power laser light |
US5643334A (en) * | 1995-02-07 | 1997-07-01 | Esc Medical Systems Ltd. | Method and apparatus for the diagnostic and composite pulsed heating and photodynamic therapy treatment |
US5728090A (en) * | 1995-02-09 | 1998-03-17 | Quantum Devices, Inc. | Apparatus for irradiating living cells |
US5755752A (en) * | 1992-04-24 | 1998-05-26 | Segal; Kim Robin | Diode laser irradiation system for biological tissue stimulation |
US5762867A (en) * | 1994-09-01 | 1998-06-09 | Baxter International Inc. | Apparatus and method for activating photoactive agents |
US5871521A (en) * | 1995-08-25 | 1999-02-16 | Matsushita Electric Industrial Co., Ltd. | Laser probe for medical treatment |
US5879376A (en) * | 1995-07-12 | 1999-03-09 | Luxar Corporation | Method and apparatus for dermatology treatment |
US5902741A (en) * | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
US5928207A (en) * | 1997-06-30 | 1999-07-27 | The Regents Of The University Of California | Microneedle with isotropically etched tip, and method of fabricating such a device |
US5928945A (en) * | 1996-11-20 | 1999-07-27 | Advanced Tissue Sciences, Inc. | Application of shear flow stress to chondrocytes or chondrocyte stem cells to produce cartilage |
US5954762A (en) * | 1997-09-15 | 1999-09-21 | Di Mino; Alfonso | Computer-controlled servo-mechanism for positioning corona discharge beam applicator |
US5958761A (en) * | 1994-01-12 | 1999-09-28 | Yeda Research And Developement Co. Ltd. | Bioreactor and system for improved productivity of photosynthetic algae |
US6042531A (en) * | 1995-06-19 | 2000-03-28 | Holcomb; Robert R. | Electromagnetic therapeutic treatment device and methods of using same |
US6045575A (en) * | 1997-09-10 | 2000-04-04 | Amt, Inc. | Therapeutic method and internally illuminated garment for the management of disorders treatable by phototherapy |
US6046046A (en) * | 1997-09-23 | 2000-04-04 | Hassanein; Waleed H. | Compositions, methods and devices for maintaining an organ |
US6060306A (en) * | 1995-06-07 | 2000-05-09 | Advanced Tissue Sciences, Inc. | Apparatus and method for sterilizing, seeding, culturing, storing, shipping and testing replacement cartilage tissue constructs |
US6063108A (en) * | 1997-01-06 | 2000-05-16 | Salansky; Norman | Method and apparatus for localized low energy photon therapy (LEPT) |
US6100290A (en) * | 1992-05-27 | 2000-08-08 | Qlt Inc. | Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases |
US6107325A (en) * | 1995-01-17 | 2000-08-22 | Qlt Phototherapeutics, Inc. | Green porphyrins as immunomodulators |
US6107608A (en) * | 1997-03-24 | 2000-08-22 | Micron Technology, Inc. | Temperature controlled spin chuck |
US6112110A (en) * | 1997-01-07 | 2000-08-29 | Wilk; Peter J. | Medical treatment system with scanner input |
US6117128A (en) * | 1997-04-30 | 2000-09-12 | Kenton W. Gregory | Energy delivery catheter and method for the use thereof |
US6179830B1 (en) * | 1996-07-24 | 2001-01-30 | J. Morita Manufacturing Corporation | Laser probe |
US6179771B1 (en) * | 1998-04-21 | 2001-01-30 | Siemens Aktiengesellschaft | Coil arrangement for transcranial magnetic stimulation |
US6198958B1 (en) * | 1998-06-11 | 2001-03-06 | Beth Israel Deaconess Medical Center, Inc. | Method and apparatus for monitoring a magnetic resonance image during transcranial magnetic stimulation |
US6210317B1 (en) * | 1998-07-13 | 2001-04-03 | Dean R. Bonlie | Treatment using oriented unidirectional DC magnetic field |
US6214035B1 (en) * | 1999-03-23 | 2001-04-10 | Jackson Streeter | Method for improving cardiac microcirculation |
US6221095B1 (en) * | 1996-11-13 | 2001-04-24 | Meditech International Inc. | Method and apparatus for photon therapy |
US6273885B1 (en) * | 1997-08-16 | 2001-08-14 | Cooltouch Corporation | Handheld photoepilation device and method |
US6277974B1 (en) * | 1999-12-14 | 2001-08-21 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
US6290713B1 (en) * | 1999-08-24 | 2001-09-18 | Thomas A. Russell | Flexible illuminators for phototherapy |
US6344050B1 (en) * | 1998-12-21 | 2002-02-05 | Light Sciences Corporation | Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue |
US20020029071A1 (en) * | 2000-03-23 | 2002-03-07 | Colin Whitehurst | Therapeutic light source and method |
US6358272B1 (en) * | 1995-05-16 | 2002-03-19 | Lutz Wilden | Therapy apparatus with laser irradiation device |
US6363285B1 (en) * | 2000-01-21 | 2002-03-26 | Albert C. Wey | Therapeutic sleeping aid device |
US6364907B1 (en) * | 1998-10-09 | 2002-04-02 | Qlt Inc. | Method to prevent xenograft transplant rejection |
US6379295B1 (en) * | 1997-09-26 | 2002-04-30 | Gilson Woo | Treatment of afflictions, ailments and diseases |
US6395016B1 (en) * | 1996-07-28 | 2002-05-28 | Biosense, Inc. | Method of treating a heart using cells irradiated in vitro with biostimulatory irradiation |
US6397107B1 (en) * | 1998-04-27 | 2002-05-28 | Bokwang Co., Ltd. | Apparatus for embolic treatment using high frequency induction heating |
US20020068927A1 (en) * | 2000-06-27 | 2002-06-06 | Prescott Marvin A. | Method and apparatus for myocardial laser treatment |
US6402678B1 (en) * | 2000-07-31 | 2002-06-11 | Neuralieve, Inc. | Means and method for the treatment of migraine headaches |
US20020087205A1 (en) * | 1999-01-15 | 2002-07-04 | Light Sciences Corporation | Transcutaneous photodynamic treatment of targeted cells |
US6421562B1 (en) * | 2000-07-17 | 2002-07-16 | Jesse Ross | Alternative treatment of a nonsurgically treatable intracranial occlusion |
US20030021124A1 (en) * | 2000-02-23 | 2003-01-30 | Jens Elbrecht | Handpiece for radiating light onto skin surface during a medical or cosmetic skin treatment |
US6514220B2 (en) * | 2001-01-25 | 2003-02-04 | Walnut Technologies | Non focussed method of exciting and controlling acoustic fields in animal body parts |
US6537301B1 (en) * | 1995-03-23 | 2003-03-25 | Tsutomu Kamei | Method of noninvasively enhancing immunosurveillance capacity and apparatus for applying pulsed light to at least forehead |
US6537304B1 (en) * | 1998-06-02 | 2003-03-25 | Amir Oron | Ischemia laser treatment |
US6551308B1 (en) * | 1997-09-17 | 2003-04-22 | Laser-Und Medizin-Technologie Gmbh Berlin | Laser therapy assembly for muscular tissue revascularization |
US6571735B1 (en) * | 2000-10-10 | 2003-06-03 | Loy Wilkinson | Non-metallic bioreactor and uses |
US20030125783A1 (en) * | 2001-12-18 | 2003-07-03 | Ceramoptec Industries, Inc. | Device and method for wound healing and debridement |
US20030125782A1 (en) * | 2001-11-15 | 2003-07-03 | Jackson Streeter | Methods for the regeneration of bone and cartilage |
US20030144712A1 (en) * | 2001-12-20 | 2003-07-31 | Jackson Streeter, M.D. | Methods for overcoming organ transplant rejection |
US20040014199A1 (en) * | 2002-01-09 | 2004-01-22 | Jackson Streeter | Method for preserving organs for transplant |
US20040030325A1 (en) * | 2001-12-05 | 2004-02-12 | Nicholas Cahir | Removable attachments for laser emitting devices |
US20040044384A1 (en) * | 2002-09-03 | 2004-03-04 | Leber Leland C. | Therapeutic method and apparatus |
US20040093042A1 (en) * | 2002-06-19 | 2004-05-13 | Palomar Medical Technologies, Inc. | Method and apparatus for photothermal treatment of tissue at depth |
US6743222B2 (en) * | 1999-12-10 | 2004-06-01 | Candela Corporation | Method of treating disorders associated with sebaceous follicles |
US20040132002A1 (en) * | 2002-09-17 | 2004-07-08 | Jackson Streeter | Methods for preserving blood |
US20040153131A1 (en) * | 2003-02-04 | 2004-08-05 | Yorke John A. | Apparatus and method for hair retention and regeneration |
US20040153130A1 (en) * | 2002-05-29 | 2004-08-05 | Amir Oron | Methods for treating muscular dystrophy |
US20050009161A1 (en) * | 2002-11-01 | 2005-01-13 | Jackson Streeter | Enhancement of in vitro culture or vaccine production using electromagnetic energy treatment |
US20050107851A1 (en) * | 2002-11-01 | 2005-05-19 | Taboada Luis D. | Device and method for providing phototherapy to the brain |
US20050159793A1 (en) * | 2002-07-02 | 2005-07-21 | Jackson Streeter | Methods for treating macular degeneration |
US7041094B2 (en) * | 1999-03-15 | 2006-05-09 | Cutera, Inc. | Tissue treatment device and method |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3375755A (en) * | 1965-10-19 | 1968-04-02 | James A. Hunt | Control device for automating sequential machine operation |
JPS5844784A (en) | 1981-09-11 | 1983-03-15 | Nippon Sekigaisen Kogyo Kk | Laser device |
DE3200584A1 (en) * | 1982-01-12 | 1983-07-21 | geb. Budwig Johanna Dr. 7290 Freudenstadt Budwig | Method for controlling the energy level, especially of the pi electrons, in water by means of a red-light laser in such a way that the water treated in this way can be used for preserving transplants |
EP0214712B1 (en) | 1985-07-31 | 1992-09-02 | C.R. Bard, Inc. | Infrared laser catheter apparatus |
IL82830A (en) | 1987-06-09 | 1992-03-29 | Simeone Rochkind | Apparatus for inducing functional regeneration of nerve fibres at an injured site of the spinal cord |
US5259380A (en) | 1987-11-04 | 1993-11-09 | Amcor Electronics, Ltd. | Light therapy system |
US5054470A (en) | 1988-03-02 | 1991-10-08 | Laboratory Equipment, Corp. | Ultrasonic treatment transducer with pressurized acoustic coupling |
IE911318A1 (en) | 1990-04-23 | 1991-10-23 | Yeda Res & Dev | Use of a tumor necrosis factor for facilitating nerve¹regeneration |
US5267294A (en) | 1992-04-22 | 1993-11-30 | Hitachi Medical Corporation | Radiotherapy apparatus |
GB9208653D0 (en) | 1992-04-22 | 1992-06-10 | Unilever Plc | Cosmetic composition and process for making it |
US5368555A (en) * | 1992-12-29 | 1994-11-29 | Hepatix, Inc. | Organ support system |
US5358503A (en) | 1994-01-25 | 1994-10-25 | Bertwell Dale E | Photo-thermal therapeutic device and method |
US5989245A (en) | 1994-03-21 | 1999-11-23 | Prescott; Marvin A. | Method and apparatus for therapeutic laser treatment |
US6156028A (en) | 1994-03-21 | 2000-12-05 | Prescott; Marvin A. | Method and apparatus for therapeutic laser treatment of wounds |
US5464436A (en) | 1994-04-28 | 1995-11-07 | Lasermedics, Inc. | Method of performing laser therapy |
JPH10509873A (en) | 1994-11-29 | 1998-09-29 | ザ ユニバーシティ オブ クイーンズランド | Remedies |
US5849585A (en) | 1995-05-10 | 1998-12-15 | Genetech, Inc. | Isolating and culturing Schwann cells |
AT403990B (en) | 1995-11-24 | 1998-07-27 | Nagypal Tibor Dipl Ing Dr | DEVICE FOR THE PHOTODYNAMIC TREATMENT OF LIVING BEINGS OR. ORGANS THE SAME |
US5842477A (en) | 1996-02-21 | 1998-12-01 | Advanced Tissue Sciences, Inc. | Method for repairing cartilage |
US5983141A (en) | 1996-06-27 | 1999-11-09 | Radionics, Inc. | Method and apparatus for altering neural tissue function |
JP3183831B2 (en) * | 1996-07-12 | 2001-07-09 | ヒロセ電機株式会社 | Lamp socket |
EP0930917B1 (en) * | 1996-07-28 | 2003-10-15 | Biosense, Inc. | Electromagnetic cardiac biostimulation |
US5817008A (en) | 1996-10-31 | 1998-10-06 | Spacelabs Medical, Inc. | Conformal pulse oximetry sensor and monitor |
US6149679A (en) | 1997-09-15 | 2000-11-21 | Adm Tronics Ulimited, Inc. | Corona discharge beam treatment of neuro-cerebral disorders |
RU2145247C1 (en) | 1998-04-10 | 2000-02-10 | Жаров Владимир Павлович | Photomatrix therapeutic device for treatment of extended pathologies |
US6663659B2 (en) | 2000-01-13 | 2003-12-16 | Mcdaniel David H. | Method and apparatus for the photomodulation of living cells |
US6471716B1 (en) | 2000-07-11 | 2002-10-29 | Joseph P. Pecukonis | Low level light therapy method and apparatus with improved wavelength, temperature and voltage control |
US6746473B2 (en) | 2001-03-02 | 2004-06-08 | Erchonia Patent Holdings, Llc | Therapeutic laser device |
US6666878B2 (en) | 2001-06-06 | 2003-12-23 | Inca Asset Management S.A. | Method and device stimulating the activity of hair follicles |
US7081128B2 (en) * | 2002-03-04 | 2006-07-25 | Hart Barry M | Phototherapy device and method of use |
-
2003
- 2003-01-08 US US10/338,949 patent/US7316922B2/en not_active Expired - Lifetime
- 2003-01-09 WO PCT/US2003/000747 patent/WO2003060399A1/en not_active Application Discontinuation
- 2003-01-09 AU AU2003207511A patent/AU2003207511A1/en not_active Abandoned
-
2007
- 2007-11-21 US US11/944,377 patent/US20080070229A1/en not_active Abandoned
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3810367A (en) * | 1970-07-16 | 1974-05-14 | W Peterson | Container for cooling, storage, and shipping of human organ for transplant |
US3735755A (en) * | 1971-06-28 | 1973-05-29 | Interscience Research Inst | Noninvasive surgery method and apparatus |
US4343301A (en) * | 1979-10-04 | 1982-08-10 | Robert Indech | Subcutaneous neural stimulation or local tissue destruction |
US4315514A (en) * | 1980-05-08 | 1982-02-16 | William Drewes | Method and apparatus for selective cell destruction |
US4633872A (en) * | 1983-11-08 | 1987-01-06 | Hgm, Incorporated | Laser optical delivery apparatus |
US4798215A (en) * | 1984-03-15 | 1989-01-17 | Bsd Medical Corporation | Hyperthermia apparatus |
US4669466A (en) * | 1985-01-16 | 1987-06-02 | Lri L.P. | Method and apparatus for analysis and correction of abnormal refractive errors of the eye |
US4850351A (en) * | 1985-05-22 | 1989-07-25 | C. R. Bard, Inc. | Wire guided laser catheter |
US4846196A (en) * | 1986-01-29 | 1989-07-11 | Wiksell Hans O T | Method and device for the hyperthermic treatment of tumors |
US5902741A (en) * | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
US5150704A (en) * | 1986-06-23 | 1992-09-29 | Fuji Electric Co., Ltd. | Laser therapeutic apparatus |
US5621091A (en) * | 1986-07-25 | 1997-04-15 | The Children's Medical Center Corporation | Probes for and nucleic acid encoding the muscular dystrophy protein, dystrophin |
US5029581A (en) * | 1986-11-19 | 1991-07-09 | Fuji Electric Co., Ltd. | Laser therapeutic apparatus |
US4930504A (en) * | 1987-11-13 | 1990-06-05 | Diamantopoulos Costas A | Device for biostimulation of tissue and method for treatment of tissue |
US4951653A (en) * | 1988-03-02 | 1990-08-28 | Laboratory Equipment, Corp. | Ultrasound brain lesioning system |
US4951482A (en) * | 1988-12-21 | 1990-08-28 | Gilbert Gary L | Hypothermic organ transport apparatus |
US5282797A (en) * | 1989-05-30 | 1994-02-01 | Cyrus Chess | Method for treating cutaneous vascular lesions |
US5441495A (en) * | 1989-08-17 | 1995-08-15 | Life Resonances, Inc. | Electromagnetic treatment therapy for stroke victim |
US5037374A (en) * | 1989-11-29 | 1991-08-06 | Carol Mark P | Stereotactic-guided radiation therapy system with variable-length compensating collimator |
US5401270A (en) * | 1990-12-19 | 1995-03-28 | Carl-Zeiss-Stiftung | Applicator device for laser radiation |
US5511563A (en) * | 1991-06-21 | 1996-04-30 | Diamond; Donald A. | Apparatus and method for treating rheumatoid and psoriatic arthritis |
US5540737A (en) * | 1991-06-26 | 1996-07-30 | Massachusetts Institute Of Technology | Minimally invasive monopole phased array hyperthermia applicators and method for treating breast carcinomas |
US5640978A (en) * | 1991-11-06 | 1997-06-24 | Diolase Corporation | Method for pain relief using low power laser light |
US5601526A (en) * | 1991-12-20 | 1997-02-11 | Technomed Medical Systems | Ultrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects |
US5501655A (en) * | 1992-03-31 | 1996-03-26 | Massachusetts Institute Of Technology | Apparatus and method for acoustic heat generation and hyperthermia |
US6033431A (en) * | 1992-04-24 | 2000-03-07 | Segal; Kim Robin | Diode laser irradiation system for biological tissue stimulation |
US5755752A (en) * | 1992-04-24 | 1998-05-26 | Segal; Kim Robin | Diode laser irradiation system for biological tissue stimulation |
US6100290A (en) * | 1992-05-27 | 2000-08-08 | Qlt Inc. | Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases |
US5622168A (en) * | 1992-11-18 | 1997-04-22 | John L. Essmyer | Conductive hydrogels and physiological electrodes and electrode assemblies therefrom |
US5627870A (en) * | 1993-06-07 | 1997-05-06 | Atea, Societe Atlantique De Techniques Avancees | Device for treating cerebral lesions by gamma radiation, and corresponding treatment apparatus |
US5445608A (en) * | 1993-08-16 | 1995-08-29 | James C. Chen | Method and apparatus for providing light-activated therapy |
US5958761A (en) * | 1994-01-12 | 1999-09-28 | Yeda Research And Developement Co. Ltd. | Bioreactor and system for improved productivity of photosynthetic algae |
US5616140A (en) * | 1994-03-21 | 1997-04-01 | Prescott; Marvin | Method and apparatus for therapeutic laser treatment |
US5762867A (en) * | 1994-09-01 | 1998-06-09 | Baxter International Inc. | Apparatus and method for activating photoactive agents |
US6107325A (en) * | 1995-01-17 | 2000-08-22 | Qlt Phototherapeutics, Inc. | Green porphyrins as immunomodulators |
US5643334A (en) * | 1995-02-07 | 1997-07-01 | Esc Medical Systems Ltd. | Method and apparatus for the diagnostic and composite pulsed heating and photodynamic therapy treatment |
US5728090A (en) * | 1995-02-09 | 1998-03-17 | Quantum Devices, Inc. | Apparatus for irradiating living cells |
US6537301B1 (en) * | 1995-03-23 | 2003-03-25 | Tsutomu Kamei | Method of noninvasively enhancing immunosurveillance capacity and apparatus for applying pulsed light to at least forehead |
US5445146A (en) * | 1995-03-31 | 1995-08-29 | Bellinger; Gary J. | Biological tissue stimulation by low level optical energy |
US6358272B1 (en) * | 1995-05-16 | 2002-03-19 | Lutz Wilden | Therapy apparatus with laser irradiation device |
US6060306A (en) * | 1995-06-07 | 2000-05-09 | Advanced Tissue Sciences, Inc. | Apparatus and method for sterilizing, seeding, culturing, storing, shipping and testing replacement cartilage tissue constructs |
US6042531A (en) * | 1995-06-19 | 2000-03-28 | Holcomb; Robert R. | Electromagnetic therapeutic treatment device and methods of using same |
US5879376A (en) * | 1995-07-12 | 1999-03-09 | Luxar Corporation | Method and apparatus for dermatology treatment |
US5871521A (en) * | 1995-08-25 | 1999-02-16 | Matsushita Electric Industrial Co., Ltd. | Laser probe for medical treatment |
US5617258A (en) * | 1995-10-25 | 1997-04-01 | Plc Medical Systems, Inc. | Non-reusable lens cell for a surgical laser handpiece |
US6179830B1 (en) * | 1996-07-24 | 2001-01-30 | J. Morita Manufacturing Corporation | Laser probe |
US6395016B1 (en) * | 1996-07-28 | 2002-05-28 | Biosense, Inc. | Method of treating a heart using cells irradiated in vitro with biostimulatory irradiation |
US6221095B1 (en) * | 1996-11-13 | 2001-04-24 | Meditech International Inc. | Method and apparatus for photon therapy |
US5928945A (en) * | 1996-11-20 | 1999-07-27 | Advanced Tissue Sciences, Inc. | Application of shear flow stress to chondrocytes or chondrocyte stem cells to produce cartilage |
US6063108A (en) * | 1997-01-06 | 2000-05-16 | Salansky; Norman | Method and apparatus for localized low energy photon therapy (LEPT) |
US6112110A (en) * | 1997-01-07 | 2000-08-29 | Wilk; Peter J. | Medical treatment system with scanner input |
US6107608A (en) * | 1997-03-24 | 2000-08-22 | Micron Technology, Inc. | Temperature controlled spin chuck |
US6117128A (en) * | 1997-04-30 | 2000-09-12 | Kenton W. Gregory | Energy delivery catheter and method for the use thereof |
US5928207A (en) * | 1997-06-30 | 1999-07-27 | The Regents Of The University Of California | Microneedle with isotropically etched tip, and method of fabricating such a device |
US6187210B1 (en) * | 1997-06-30 | 2001-02-13 | The Regents Of The University Of California | Epidermal abrasion device with isotropically etched tips, and method of fabricating such a device |
US6273885B1 (en) * | 1997-08-16 | 2001-08-14 | Cooltouch Corporation | Handheld photoepilation device and method |
US6045575A (en) * | 1997-09-10 | 2000-04-04 | Amt, Inc. | Therapeutic method and internally illuminated garment for the management of disorders treatable by phototherapy |
US5954762A (en) * | 1997-09-15 | 1999-09-21 | Di Mino; Alfonso | Computer-controlled servo-mechanism for positioning corona discharge beam applicator |
US6551308B1 (en) * | 1997-09-17 | 2003-04-22 | Laser-Und Medizin-Technologie Gmbh Berlin | Laser therapy assembly for muscular tissue revascularization |
US6046046A (en) * | 1997-09-23 | 2000-04-04 | Hassanein; Waleed H. | Compositions, methods and devices for maintaining an organ |
US6379295B1 (en) * | 1997-09-26 | 2002-04-30 | Gilson Woo | Treatment of afflictions, ailments and diseases |
US6179771B1 (en) * | 1998-04-21 | 2001-01-30 | Siemens Aktiengesellschaft | Coil arrangement for transcranial magnetic stimulation |
US6397107B1 (en) * | 1998-04-27 | 2002-05-28 | Bokwang Co., Ltd. | Apparatus for embolic treatment using high frequency induction heating |
US6918922B2 (en) * | 1998-06-02 | 2005-07-19 | Amir Oron | Ischemia laser treatment |
US6537304B1 (en) * | 1998-06-02 | 2003-03-25 | Amir Oron | Ischemia laser treatment |
US6198958B1 (en) * | 1998-06-11 | 2001-03-06 | Beth Israel Deaconess Medical Center, Inc. | Method and apparatus for monitoring a magnetic resonance image during transcranial magnetic stimulation |
US6210317B1 (en) * | 1998-07-13 | 2001-04-03 | Dean R. Bonlie | Treatment using oriented unidirectional DC magnetic field |
US6364907B1 (en) * | 1998-10-09 | 2002-04-02 | Qlt Inc. | Method to prevent xenograft transplant rejection |
US6344050B1 (en) * | 1998-12-21 | 2002-02-05 | Light Sciences Corporation | Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue |
US20020087205A1 (en) * | 1999-01-15 | 2002-07-04 | Light Sciences Corporation | Transcutaneous photodynamic treatment of targeted cells |
US6602274B1 (en) * | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
US7041094B2 (en) * | 1999-03-15 | 2006-05-09 | Cutera, Inc. | Tissue treatment device and method |
US6214035B1 (en) * | 1999-03-23 | 2001-04-10 | Jackson Streeter | Method for improving cardiac microcirculation |
US6273905B1 (en) * | 1999-03-23 | 2001-08-14 | Jackson Streeter | Method for treating spinal cord transection |
US6267780B1 (en) * | 1999-03-23 | 2001-07-31 | Jackson Streeter | Method for treating musculoskeletal injury |
US6290713B1 (en) * | 1999-08-24 | 2001-09-18 | Thomas A. Russell | Flexible illuminators for phototherapy |
US6743222B2 (en) * | 1999-12-10 | 2004-06-01 | Candela Corporation | Method of treating disorders associated with sebaceous follicles |
US6277974B1 (en) * | 1999-12-14 | 2001-08-21 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
US6363285B1 (en) * | 2000-01-21 | 2002-03-26 | Albert C. Wey | Therapeutic sleeping aid device |
US20030021124A1 (en) * | 2000-02-23 | 2003-01-30 | Jens Elbrecht | Handpiece for radiating light onto skin surface during a medical or cosmetic skin treatment |
US20020029071A1 (en) * | 2000-03-23 | 2002-03-07 | Colin Whitehurst | Therapeutic light source and method |
US20020068927A1 (en) * | 2000-06-27 | 2002-06-06 | Prescott Marvin A. | Method and apparatus for myocardial laser treatment |
US6421562B1 (en) * | 2000-07-17 | 2002-07-16 | Jesse Ross | Alternative treatment of a nonsurgically treatable intracranial occlusion |
US6402678B1 (en) * | 2000-07-31 | 2002-06-11 | Neuralieve, Inc. | Means and method for the treatment of migraine headaches |
US6571735B1 (en) * | 2000-10-10 | 2003-06-03 | Loy Wilkinson | Non-metallic bioreactor and uses |
US6514220B2 (en) * | 2001-01-25 | 2003-02-04 | Walnut Technologies | Non focussed method of exciting and controlling acoustic fields in animal body parts |
US20030125782A1 (en) * | 2001-11-15 | 2003-07-03 | Jackson Streeter | Methods for the regeneration of bone and cartilage |
US20040030325A1 (en) * | 2001-12-05 | 2004-02-12 | Nicholas Cahir | Removable attachments for laser emitting devices |
US20030125783A1 (en) * | 2001-12-18 | 2003-07-03 | Ceramoptec Industries, Inc. | Device and method for wound healing and debridement |
US20030144712A1 (en) * | 2001-12-20 | 2003-07-31 | Jackson Streeter, M.D. | Methods for overcoming organ transplant rejection |
US20040014199A1 (en) * | 2002-01-09 | 2004-01-22 | Jackson Streeter | Method for preserving organs for transplant |
US20040153130A1 (en) * | 2002-05-29 | 2004-08-05 | Amir Oron | Methods for treating muscular dystrophy |
US20040093042A1 (en) * | 2002-06-19 | 2004-05-13 | Palomar Medical Technologies, Inc. | Method and apparatus for photothermal treatment of tissue at depth |
US20050159793A1 (en) * | 2002-07-02 | 2005-07-21 | Jackson Streeter | Methods for treating macular degeneration |
US20040044384A1 (en) * | 2002-09-03 | 2004-03-04 | Leber Leland C. | Therapeutic method and apparatus |
US20040132002A1 (en) * | 2002-09-17 | 2004-07-08 | Jackson Streeter | Methods for preserving blood |
US20050009161A1 (en) * | 2002-11-01 | 2005-01-13 | Jackson Streeter | Enhancement of in vitro culture or vaccine production using electromagnetic energy treatment |
US20050107851A1 (en) * | 2002-11-01 | 2005-05-19 | Taboada Luis D. | Device and method for providing phototherapy to the brain |
US20040153131A1 (en) * | 2003-02-04 | 2004-08-05 | Yorke John A. | Apparatus and method for hair retention and regeneration |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10758743B2 (en) | 2001-11-01 | 2020-09-01 | Pthera LLC | Method for providing phototherapy to the brain |
US8167921B2 (en) | 2003-01-24 | 2012-05-01 | Jackson Streeter | Low level light therapy for enhancement of neurologic function |
US20080004565A1 (en) * | 2003-01-24 | 2008-01-03 | Jackson Streeter | Method of treating or preventing depression |
US11179572B2 (en) | 2006-01-30 | 2021-11-23 | Pthera LLC | Light-emitting device and method for providing phototherapy to the brain |
US20100016841A1 (en) * | 2006-01-30 | 2010-01-21 | Luis De Taboada | Light-emitting device and method for providing phototherapy to the brain |
US10188872B2 (en) | 2006-01-30 | 2019-01-29 | Pthera LLC | Light-emitting device and method for providing phototherapy to the brain |
US8308784B2 (en) | 2006-08-24 | 2012-11-13 | Jackson Streeter | Low level light therapy for enhancement of neurologic function of a patient affected by Parkinson's disease |
US20080125836A1 (en) * | 2006-08-24 | 2008-05-29 | Jackson Streeter | Low level light therapy for enhancement of neurologic function of a patient affected by parkinson's disease |
US20100003782A1 (en) * | 2008-07-02 | 2010-01-07 | Nishant Sinha | Methods Of Forming A Non-Volatile Resistive Oxide Memory Cell And Methods Of Forming A Non-Volatile Resistive Oxide Memory Array |
US8149526B2 (en) | 2008-09-18 | 2012-04-03 | Photothera, Inc. | Single use lens assembly |
US20110102916A1 (en) * | 2008-09-18 | 2011-05-05 | Photo Thera, Inc. | Single-use lens assembly |
US10071259B2 (en) | 2008-09-18 | 2018-09-11 | Pthera, Llc | Optical assembly |
US9610460B2 (en) | 2009-05-01 | 2017-04-04 | Wayne State University | Light therapy treatment |
US10071261B2 (en) | 2009-05-01 | 2018-09-11 | Wayne State University | Light therapy treatment |
US11020604B2 (en) | 2009-05-01 | 2021-06-01 | Wayne State University | Light therapy treatment |
US8303636B2 (en) | 2009-08-12 | 2012-11-06 | Fredric Schiffer | Methods for treating psychiatric disorders using light energy |
US8574279B2 (en) | 2009-08-12 | 2013-11-05 | Joulesafe, Llc | Methods for treating psychiatric disorders using light energy |
US20110040356A1 (en) * | 2009-08-12 | 2011-02-17 | Fredric Schiffer | Methods for Treating Psychiatric Disorders Using Light Energy |
US9426979B2 (en) | 2011-03-15 | 2016-08-30 | Paragonix Technologies, Inc. | Apparatus for oxygenation and perfusion of tissue for organ preservation |
US9253976B2 (en) | 2011-03-15 | 2016-02-09 | Paragonix Technologies, Inc. | Methods and devices for preserving tissues |
US11178866B2 (en) | 2011-03-15 | 2021-11-23 | Paragonix Technologies, Inc. | System for hypothermic transport of samples |
US8828710B2 (en) | 2011-03-15 | 2014-09-09 | Paragonix Technologies, Inc. | System for hypothermic transport of samples |
US9867368B2 (en) | 2011-03-15 | 2018-01-16 | Paragonix Technologies, Inc. | System for hypothermic transport of samples |
US9936689B2 (en) | 2011-03-15 | 2018-04-10 | Paragonix Technologies, Inc. | Methods and devices for preserving tissues |
US11089775B2 (en) | 2011-03-15 | 2021-08-17 | Paragonix Technologies, Inc. | System for hypothermic transport of samples |
US8835158B2 (en) | 2011-03-15 | 2014-09-16 | Paragonix Technologics, Inc. | Apparatus for oxygenation and perfusion of tissue for organ preservation |
US9451788B2 (en) * | 2012-03-16 | 2016-09-27 | Seung Won Lee | Storage apparatus for improving food preservation |
US20140311359A1 (en) * | 2012-03-16 | 2014-10-23 | Seung Won Lee | Storage apparatus for improving food preservation |
US8785116B2 (en) | 2012-08-10 | 2014-07-22 | Paragonix Technologies, Inc. | Methods for evaluating the suitability of an organ for transplant |
US9155297B2 (en) | 2012-08-10 | 2015-10-13 | Paragonix Technologies, Inc. | Methods and systems for assessing the suitability of an organ for transplant |
US9560846B2 (en) | 2012-08-10 | 2017-02-07 | Paragonix Technologies, Inc. | System for hypothermic transport of biological samples |
JP2015035999A (en) * | 2013-08-12 | 2015-02-23 | 株式会社コーナン・メディカル | Apparatus for observing cornea for transplantation, and auxiliary light source used for the same |
USD819223S1 (en) | 2014-10-10 | 2018-05-29 | Paragonix Technologies, Inc. | Transporter for a tissue transport system |
US11166452B2 (en) | 2017-06-07 | 2021-11-09 | Paragonix Technologies, Inc. | Apparatus for tissue transport and preservation |
US11659834B2 (en) | 2017-06-07 | 2023-05-30 | Paragonix Technologies, Inc. | Apparatus for tissue transport and preservation |
US11632951B2 (en) | 2020-01-31 | 2023-04-25 | Paragonix Technologies, Inc. | Apparatus for tissue transport and preservation |
Also Published As
Publication number | Publication date |
---|---|
US7316922B2 (en) | 2008-01-08 |
AU2003207511A1 (en) | 2003-07-30 |
WO2003060399A1 (en) | 2003-07-24 |
US20040014199A1 (en) | 2004-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7316922B2 (en) | Method for preserving organs for transplant | |
US20040132002A1 (en) | Methods for preserving blood | |
US20200359618A1 (en) | Preservation and transport of an ex vivo biological sample comprising ultrasound application | |
AU2006312293B2 (en) | Compositions and methods for the evaluation and resuscitation of cadaveric hearts for transplant | |
Capella et al. | Preservation of viable corneal tissue | |
US20030144712A1 (en) | Methods for overcoming organ transplant rejection | |
US20080160496A1 (en) | Preserved Viable Cartilage, Method for Its Preservation, and System and Devices Used Therefor | |
CN111685105A (en) | Isolated organ keeps device | |
MX9705540A (en) | Method and package design for cryopreservation and storage of cultured tisse equivalents. | |
Almodin et al. | Recovery of natural fertility after grafting of cryopreserved germinative tissue in ewes subjected to radiotherapy | |
US20030212442A1 (en) | Low level light therapy for the treatment of myocardial infarction | |
JP2015174823A (en) | Preservation method of biomaterial, production procedure of biomaterial, biomaterial, transplant material, transplant method and preservation apparatus of biomaterial | |
KAROW et al. | Preservation of hearts by freezing | |
Kim | Time to re-think: ovarian tissue transplantation versus whole ovary transplantation | |
Elami et al. | Successful restoration of function of frozen and thawed isolated rat hearts | |
Blanchard et al. | Techniques for perfusion and storage of heterotopic heart transplants in mice | |
US20050026132A1 (en) | Warm intermittent perfusion | |
US20130177898A1 (en) | Method of Treating Organs | |
Ozgur et al. | Current practice and novel approaches in organ preservation | |
RU2794963C1 (en) | Method for optimizing cryopreservation of ovarian tissue for long-term storage | |
JP2018016654A (en) | Method for preserving biomaterial, method for producing biomaterial, biomaterial, implantation material and biomaterial preservation device | |
RU2783910C2 (en) | Method for producing a homograft of the cardiovascular system by means of cryo-conservation | |
US20230380413A1 (en) | Method and device to preserve organs and tissue for transplantation | |
KR20170098657A (en) | Removing the hair follicles working board | |
Bates | Overcoming Challenges in Organ Transplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LIGHTHOUSE CAPITAL PARTNERS VI, L.P., CALIFORNIA Free format text: SECURITY AGREEMENT;ASSIGNOR:PHOTOTHERA, INC.;REEL/FRAME:021462/0135 Effective date: 20080829 Owner name: LIGHTHOUSE CAPITAL PARTNERS VI, L.P.,CALIFORNIA Free format text: SECURITY AGREEMENT;ASSIGNOR:PHOTOTHERA, INC.;REEL/FRAME:021462/0135 Effective date: 20080829 |
|
AS | Assignment |
Owner name: WARBURG PINCUS PRIVATE EQUITY IX, L.P., NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:PHOTOTHERA, INC.;REEL/FRAME:021462/0922 Effective date: 20080829 Owner name: WARBURG PINCUS PRIVATE EQUITY IX, L.P.,NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:PHOTOTHERA, INC.;REEL/FRAME:021462/0922 Effective date: 20080829 |
|
AS | Assignment |
Owner name: PHOTOTHERA, INC., CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:LIGHTHOUSE CAPITAL PARTNERS VI, L.P.;REEL/FRAME:022678/0273 Effective date: 20090513 Owner name: PHOTOTHERA, INC.,CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:LIGHTHOUSE CAPITAL PARTNERS VI, L.P.;REEL/FRAME:022678/0273 Effective date: 20090513 |
|
AS | Assignment |
Owner name: PHOTOTHERA, INC., CALIFORNIA Free format text: TERMINATION OF PATENT SECURITY AGREEMENT;ASSIGNOR:WARBURG PINCUS PRIVATE EQUITY IX, L.P.;REEL/FRAME:022722/0784 Effective date: 20090427 |
|
AS | Assignment |
Owner name: COMERICA BANK, MICHIGAN Free format text: SECURITY AGREEMENT;ASSIGNOR:PHOTOTHERA, INC.;REEL/FRAME:025829/0859 Effective date: 20110211 Owner name: OXFORD FINANCE CORPORATION, VIRGINIA Free format text: SECURITY AGREEMENT;ASSIGNOR:PHOTOTHERA, INC.;REEL/FRAME:025829/0859 Effective date: 20110211 |
|
AS | Assignment |
Owner name: PHOTOTHERA, INC., CALIFORNIA Free format text: TERMINATION OF PATENT SECURITY AGREEMENT;ASSIGNOR:WARBURG PINCUS PRIVATE EQUITY IX, L.P.;REEL/FRAME:027898/0121 Effective date: 20090427 |
|
XAS | Not any more in us assignment database |
Free format text: TERMINATION OF PATENT SECURITY AGREEMENT;ASSIGNOR:WARBURG PINCUS PRIVATE EQUITY IX, L.P.;REEL/FRAME:027898/0121 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |